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ABSTRACT 
 
The TRIP-Br proteins are a novel family of transcriptional regulators that function at 
E2F1-responsive promoters to integrate signals provided by PHD zinc finger- and/or 
bromodomain-containing transcription factors. Multiple members of TRIP-Br family 
are demonstrated to be oncogenes. We have previously reported that antagonism of 
the TRIP-Br integrator function by synthetic decoy peptides that compete with TRIP-
Br1/2 for binding to PHD zinc finger- and/or bromodomain-containing transcription 
factors inhibit the growth of human osteosarcoma cell line U2OS through the 
transcriptional downregulation of a subset of endogenous E2F1-responsive genes. In 
this study, we demonstrated that antagonism of the interactor function  TRIP‑Br1/2 
by these synthetic decoy peptides elicited an anti-proliferative effect in representative 
human nasopharyngeal (CNE2), cervical (Ca Ski) and melanoma (MeWo) cancer cell 
lines in vitro as well as in corresponding chick embryo chorioallantoic membrane 
(CAM) tumor xenografts in vivo, suggesting that TRIP‑Br1 may represent a novel 
therapeutic target for the treatment of human cutaneous and intracavitary 
hyperproliferative lesions.  To further understand the regulation of this potential 
therapeutic target, GST-mTRIP-Br1 fusion protein was used as “bait” to mix with 
HEK293 whole cell lysate to identify cellular interacting proteins.  Mass spectroscopy 
identified serine/threonine protein phosphatase 2A (PP2A) Bα and Bβ regulatory 
subunit as TRIP-Br-1 interactors.  GST pull-down, co-immunoprecipitation and 
immunofluorescence staining independently confirmed the interaction between 
endogenous PP2A and TRIP-Br1. Immunoprecipitation of TRIP-Br1 protein followed 
by immunodetection of phosphoserine residues with anti-phosphoserine antibody 
demonstrated that TRIP-Br-1 is a serine-phosphorylated protein. Inhibition of PP2A 
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activity by okadaic acid or transcriptional silencing of PP2A catalytic subunit resulted 
in an increase in serine phosphorylated TRIP-Br1 and a decrease in steady-state level 
of TRIP-Br1 protein. Furthermore, overexpression of the PP2A-C subunit increased 
the TRIP-Br1 protein level and TRIP-Br1 co-activated of E2F1/DP1 transcription. 
These results suggest that PP2A holoenzyme ABαC associates with TRIP-Br1 in vitro 
and in vivo in mammalian cells. The level of TRIP-Br1 protein is positively regulated 
by PP2A. In summary, our data indicates that antagonizing the integrator function of 
TRIP-Br proto-oncoprotein may represent important chemotherapeutic drug target for 
superficial cutaneous and intracavitary hyperproliferative lesions. The protein level of 
TRIP-Br1 is positively regulates by serine/threonine protein phosphatase 2A, via 
dephoshrlation of serine residue(s) on TRIP-Br1. Uncovering the mechanism of 
TRIP-Br protein regulation will facilitate the application of therapeutic strategies 
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1.1  TRIP-Br proteins 
 
1.1.1  TRIP-Br protein family 
 
TRIP-Br (Transcriptional Regulator Interacting with the PHD-Bromodomain) protein 
family is a novel family of proteins that function in both gene transcriptional 
regulation and cell cycle progression. It comprises four structurally and functionally 
related mammalian proteins (TRIP-Br1, TRIP-Br2, RBT1 and CDCA4) and a 
Drosophila homologue, TARA. Murine TRIP-Br1 (p34SEI-1/SEI-1/SERTAD1) was 
originally identified from a mouse whole embryo cDNA library based on its unique 
ability to interact with the composite PHD-bromodomain of the transcription factor 
KRIP-1 (KRAB associated protein, also known as TIF1β or KAP 1) in a yeast two-
hybrid screen (Hsu et al., 2001). TRIP-Br1 is identical to p34SEI-1, which was cloned 
using the cyclin-dependent kinase (CDK) inhibitor INK4 family member p16INK4a as 
the “bait” (Sugimoto et al., 1999).  As TRIP-Br2 (SE1-2/SERTAD2) was 
demonstrated to be structurally and functionally homologous to TRIP-Br1, they were 
designated as a novel family of proteins (Hsu et al., 2001). CDCA4/Hepp/SEI-3 was 
identified as a gene specifically expressed in hematopoietic progenitor cells as 
opposed to hematopoietic stem cells (Abdullah et al., 2001; Cho et al., 2000). 
Subsequently, RBT1 (SERTAD3) was cloned in a yeast two-hybrid screen employing 
the replication protein A (RPA) 32 subunit as the “bait.” Recently, SERTAD4 was 
reported to be a non-classical member of this protein family, as it only harbors two of 
the four characteristic domains of TRIP-Br protein family (Bennetts et al., 2006). 
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Along with the Drosophila protein taranis (TARA), a novel member of the trithorax 
group of regulatory molecules isolated in a screen for functional partners of the 
homeotic loci, members of the TRIP-Br family share at least 4 characteristic highly 
evoluationarily conserved domains (Figure 1.1) (Calgaro et al., 2002).  
 
BLAST analysis shows that sequences for CDCA4 and TRIP-Br2 orthologues are 
present in a range of species including human, mouse, pufferfish, fugu, zebrafish, etc; 
while orthologues for RBT1 and TRIP-Br1 have only been identified from mammalian 
sequences, suggesting that the RBT1 and TRIP-Br1 genes exist only in mammals 
(Bennetts et al., 2006). A comparison of nomenclature, protein cellular localization, 
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Figure 1.1: Comparison of the motif structure of five classic members (TRIP-Br1, 
TRIP-Br2, RBT1, CDCA4 and TARA) and one non-classical member of TRIP-
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Table 1.1: Summary on the nomenclature, protein cellular localization, tissue 




Tissue  Expression Protein Function(s) 
Human TRIP-









pattern (Lai et al., 
2007; Sugimoto 
et al,1999) 
Ubiquitously expressed in 
various human adult 
tissues except thymus 




proteins to regulate E2F1/DP1 
mediated transcription via 
interaction with DP1 (Hsu, et 
al,  2001); regulates cyclin D1-
CDK4 complex activity by 
antagonizing the inhibitory 
action of the tumor suppressor 
p16INK4α, leading to stimulation 
of cyclin D1-cdk4 kinase 















pattern (Lai et al., 
2007) 
Ubiquitously expressed at 
similar levels in the 
majority of human adult 
tissues and during 
development, with 
slightly higher level in 
thymus and peripheral 
blood leukocytes (Nagase 
et al., 1997)  
Associates with PHD-
bromodomain-containing 
proteins to activate E2F1/DP1 
mediated transcription via 
interaction with DP1 (Hsu, et 













pattern (Lai et al., 
2007) 




10.5), adult mouse 
thymus, bone and B- and 
T-cells (Lai et al., 2007) 
Represses E2F1-dependent 
transcriptional activation and 
cell proliferation 











pattern (Cho et 
al., 2000; 
Darwish et al., 
2007) 
Ubiquitous expression 
in all human adult tissues 
examined (Cho et al., 
2000; Darwish et al., 
2007)  
Potentiates E2F-1 
transcriptional activity and 
positively regulate cell 
proliferation (Cho et al., 2000; 




Unknown High expression levels in 
human adult epidermal 
tissues and in digits 





Unknown Broad expression 
throughout Drosophila 
embryogenesis. Different 
staining pattern of α- and 
β- isoforms (Calgaro et 
al., 2002) 
Proposed to modify expression 
of the homeotic loci by binding 
and activating bromodomain-
containing trxG proteins to 
promote an active chromatin 
state (Calgaro et al., 2002) 
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1.1. 2   Domain Structure of the TRIP-Br Proteins 
 
Similarities among the above five mammalian TRIP-Br/TRIP-Br-like proteins are 
based on the presence of multiple highly evolutionarily conserved domains. As 
showed in Figure 1.1, these regions include an N-terminal basic cyclin A-binding 
motif (containing a putative nuclear localization signal), a novel uncharacterized 
motif termed SERTA (SEI-1, RBT1 and TARA), a PHD zinc finger- and/or 
bromodomain-containing protein binding motif, and a conserved acidic C-terminal 
domain (shown to mediate a transactivation function for TRIP-Br1 and TRIP-Br2) 
(Calgaro et al., 2002).  All four domains are highly evolutionarily conserved across 
mammalian species. The SERTA motif is the longest among them, consisting of 
approximately forty-eight amino acids. This domain may serve as a protein-protein 
interaction domain for the binding of TRIP-Br1 to CDK4  (see Table 1.1) involved in 
the regulation of the activity of the cyclin-D1/CDK4/p16INK4α complex, which 
promotes cell cycle progression in early G1 (Sugimoto et al., 1999). The putative 
cyclin A-binding motif in the TRIP-Br proteins family was suggested based on the 
significant homology of this domain in the TRIP-Br1 and TRIP-Br2 proteins with the 
cyclin A binding motif in the E2F-1 transcriptional activator (Hsu et al., 2001). The 
binding TRIP-Br1/2 with cyclin A in vitro and in vivo has been confirmed 
experimentally (S.I. Hsu, unpublished data). The C-terminal region of TRIP-Br 
proteins is rich in acidic amino acids; recruitment of this region to a target promoter 
activates transcription (Hsu et al., 2001). The PHD zinc finger- and bromodomain-
interacting motif is a unique motif that allows TRIP-Br proteins to physically interact 
with a host of PHD zinc finger- and/or bromodomain-containing proteins that play 
important roles in transcription regulation and chromatin remodeling. Figure 1.1 
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shows a comparison of the motif structure of five classic members of TRIP-Br 
proteins and one non-classical member of TRIP-Br protein member, SERTAD 4. 
 
1.1.3  TRIP-Br proteins co-regulate the gene transcriptional 
activity of E2F1/DP-1 
 
To date, all four classic members of the mammalian TRIP-Br protein family have 
been reported to possess potent intrinsic transcriptional activity. It was first noted that 
GAL4-TRIP-Br1 and GAL4-TRIP-Br2 fusion protein stimulates both basal and 
enhancer-activated transcription when recruited to a heterologous promoter bearing 
GAL4 DNA binding site (Hsu et al., 2001). Thereafter, potent transactivation activity 
was demonstrated for the RBT-1 and CDCA4 proteins (Cho et al., 2000; Hayashi et 
al., 2006). Truncation analysis suggests that the transcription domain of the four 
TRIP-Br proteins all lie within the acidic C-terminus. Deletion of residues 122-236 in 
TRIP-Br1, residues 235-311 in TRIP-Br2 and residues 171-241 in CDCA4 
completely abolished their transcriptional activity (Hayashi et al., 2006; Hsu et al., 
2001).  Notably, each of these mapped regions overlap with the PHD zinc finger- and 
bromodomain- interacting motif, suggesting that these two characteristic motifs of 
TRIP-Br proteins may be involved in mediating a transactivation function. The N-
terminal region including the SERTA motif appears to function to inhibit 
transactivation within the CDCA4 protein, as deletion of this region strongly 
enhanced luciferase reporter transactivation by the CDCA4 protein (Hayashi et al., 
2006). 
 
More importantly, TRIP-Br proteins have also been shown to be able to regulate the 
transcriptional activity of the E2F1/DP1 complex on E2F1-dependent gene promoters. 
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Co-expression of TRIP-Br1 or TRIP-Br2 with E2F1/DP1 resulted in the stimulation 
of transcriptional activity of luciferase reporters bearing promoter regions containing 
the consensus E2F1 binding sequences of multiple human E2F1-dependent genes 
(Hsu et al., 2001). The magnitude of the co-activation by TRIP-Br proteins was 
similar to that observed for MDM2, a known E2F1 interactor that stimulates 
transcriptional activity and DNA synthesis (Hsu et al., 2001). Further investigations 
determined that TRIP-Br1 and TRIP-Br2 bind DP1 but not E2F1, which may 
constitute the basis of TRIP-Br protein- mediated E2F1/DP1 transcriptional co-
activation (Hsu et al., 2001). To date, the region of TRIP-Br1 and TRIP-Br2 that 
interacts with DP1 has not been determined. Similar to the E2F1/DP1 transcriptional 
co-activation activities exhibited by TRIP-Br1 and TRIP-Br2, RBT1 also potentiates 
E2F1 transcriptional activity (Darwish et al., 2007). Interestingly, CDCA4 exhibits 
the opposite effect on the transcriptional activity of the E2F1/DP1 transcription 
complex despite the high sequence homology of CDCA4 with other members of 
TRIP-Br protein family and the similar C-terminal transcriptional activity of CDC4A 
when recruited to a heterologous reporter (Hayashi et al., 2006).  In addition, reporter 
transcriptional activity induced by E2F1, E2F2 and E2F3 is completely suppressed by 
the coexpression of CDCA4 (Hayashi et al., 2006).  Notably, phylogenetic analysis of 
human TRIP-Br family members based on the ClustalW algorithm reveals that the 
human CDCA4 protein is the most remotely related to other proteins among TRIP-Br 
family proteins (Hayashi et al., 2006). The unexpected effect of CDCA4 on E2F-
induced transcriptional activity may be a reflection of evolutionary divergence and 
diversification of function of the TRIP-Br protein family.  
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1.1.4    TRIP-Br proteins interact with PHD zinc finger- and 
/or bromodomain-containing proteins  
 
1.1.4.1  PHD zinc finger domain and proteins 
 
The plant homeodomain (PHD) and zinc finger domain is an evolutionarily conserved 
zinc-coordinating structural motif that is present in a wide variety of eukaryotic 
proteins (Bienz, 2006).  It comprises 60 amino acids, typically defined by a C4HC3 
signature (four cysteines, one histidine, three cysteines) with a characteristic cysteine 
spacing and with additional conserved residues, a tryptophan or other aromatic amino 
acid preceding the final cysteine pair (Figure 1.2) (Bienz, 2006). PHD zinc finger 
domain has nucleosome-binding activity. For example, the isolated PHD zinc finger- 
of p300, a transcriptional coactivator with histone acetyltransferase (HAT) activity, 
was shown to have nucleosome-binding activity in an electrophoretic mobility shift 
assay (Ragvin et al., 2004). PHD zinc finger-s play important roles in the recognition 
and remodeling of chromatin and the regulation of transcriptional activity through 
interacting with trimethylated lysine 4 on histone 3 (H3K4), a universal modification 
in the upstream 5’ regulatory regions of active genes (Mellor, 2006).  The 
transcriptional co-repressor KRIP-1, for instance, binds methylated histones via its 
PHD zinc finger- domain and functions to recruit KRAB domain proteins to convert 
open chromatin into silenced chromatin  (Ragvin et al., 2004). 
 
There are ~150 PHD zinc finger-containing genes in the human genome, a subset of 
which have been implicated in human disease, especially developmental disorders. A 
well-known example is CBP (Cyclic-AMP-response element Binding Protein). 
Deletions, translocations, or point mutations in the CBP gene which alter the histone 
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acetyltransferase activity (HAT) of the encoded mutant protein lead to Rubinstein-
Taybi Syndrome (RTS), a human developmental disorder comprised by mental 
retardation, an unusual facial appearance, broad thumbs, and broad big toes (Murata 
et al., 2001; Rubinstein and Taybi, 1963). Missense and truncation mutations of PHF6 
(Plant Homeodomain-like Finger- Protein 6) are associated with Börjeson−Forssman 
−Lehmann syndrome, a mental retardation syndrome characterized by hypogonadism, 
obesity, facial anomalies and epilepsy (Lower et al., 2002). PHF8 (Plant 
Homeodomain-like Finger- Protein 8) is involved in Siderius–Hamel cleft lip or 
palate syndrome associated with cleft lip or cleft palate (Ropers and Hamel, 2005). 
Mutations in WSTF (William–Beuren Syndrome Transcription Factor) have been 
implicated in Williams-Beuren syndrome, a genetic condition characterized by 
cardiac defects, suggestive facial dysmorphism and specific cognitive and behavioral 
alterations (Mila et al., 1999). Mutations that disrupt one or more of the zinc 
coordinating cysteine residues of the ATRX protein (α-Thalassemia, mental 
Retardation, X-linked) have been implicated in the X-linked α-thalassemia/mental 
retardation syndrome (ATR-X) (Gibbons and Higgs, 2000).  Mutation of PHD zinc 
finger-containing genes like Mi-2 and AIRE (AutoImmune REgulator) also lead to 
dermatomyositis and the Autoimmune Polyendocrinopathy Syndrome Type 1, 
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Figure 1.2: The predicted cross-brace (C4HC3) model of the PHD zinc 
finger domain of Pygopus.  
 
Residues conserved among the Pygopus orthologues are in green; red rings mark loop 
1 and loop 2 residues with the indicated functional relevance. Figure source: Bienz, 
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1.1.4.2  Bromodomain and bromodomain-containing proteins 
 
The bromodomain is a ~110 amino acid structural module encoding four amphipathic 
α-helical subdomains (Figure1.3). A significant subset of chromatin-associated 
proteins, nuclear histone acetyltransferases (HATs), histone deacetylases, histone 
methyltransferases and histone kinases possess this domain (Yang, 2004). Recent 
evidence from NMR spectroscopy strongly suggests that a role for this domain in the 
recognition of acetyl-lysine residues in the histone tails (Zeng and Zhou, 2002). 
Recognition of histone acetyllysine residues is often a prerequisite for protein-histone 
association and chromatin remodeling. To date, lysine acetylation is reported to occur 
in over 40 transcription factors that exhibit sequence-specific DNA binding and to 
affect their DNA binding affinity, coregulator association, nuclear localization, 
phosphorylation, ubiquitination and stability (Yang, 2004). In most cases, this 
modification potentiates transcription (Zeng and Zhou, 2002).  Acetylation of a few 
transcription factors like NF-κB, RelA and TCF (Drosophila) inhibits transcription, 
which may serve as a negative feedback mechanism to control the duration of 
transcription (Yang, 2004). 
 
At least five physiologically significant functional roles have been described for the 
bromodomain. Firstly, the bromodomain is important for chromatin acetylation by 
HATs. For instance, the yeast Gcn5 (General control non-derepressible 5) protein is 
the catalytic subunit of multiple HAT complexes that couple acetyltransferase activity 
to the acetyllysine binding ability. The bromodomain of Gcn5 is required for 
anchoring the SAGA (Spt-Ada-Gcn5-Acetyltransferase) (Carrozza et al., 2003). 
Second, the bromodomain contributes to acetylation-dependant nucleosome assembly 
and remodeling. The bromodomain of Swi2/Snf2 is important for the association of 
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this transcriptional regulatory complex with acetylated nucleosomes and its 
synergistic function with yeast Gcn5 in mediating chromatin acetylation and 
remodeling (Fry and Peterson, 2001).  Third, the bromodomain is involved in 
organizing chromosome or chromatin domains. Brd4/MCAP (Mitotic Chromosome-
Associated Protein) interacts with acetylated chromatin during interphase and mitosis; 
Brd5/BRDT (BRomoDomain Testis-specific) can dramatically reorganize chromatin 
in an acetylation-dependent manner (Dey et al., 2003; Pivot-Pajot et al., 2003). Fourth, 
bromodomains also recognize acetylated nonhistone proteins. Acetylation of p53 and 
c-Myb promotes their association with bromodomain-containing HATs (Sano and 
Ishii, 2001). Lastly, in addition to acetyllysine recognition, bromodomains display 
other activities. It has been reported that the bromodomain of p300 binds to histones 
in an acetylation-independent manner. Some evidences also support the proposal that 
a subset of bromodomains function as classic protein- or DNA-binding modules 
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Figure 1.3: The NMR solution structure of the P/CAF bromodomain (blue) in 
complex with an lysine-acetylated peptide (green) derived from HIV-1 Tat at 
residue K50 (SYGR-AcK-KRRQR). Figure source: Yang, 2004. (Reprinted with 
permission of Wiley-Liss, Inc. Wiley a subsidiary of John Wiley & Sons, Inc.) 
 
Table 1.2: Representative bromodomain proteins in yeast and mammals. (Table 
source: Zeng and Zhou, 2002). Permission to cite copyright work has been granted. 
 
 
aKnown acetyllysine-binding ability. bPHD, plant homeodomain-linked zinc finger; DDT, a 
well-characterized DNA-binding homeobox-domain and other conserved domains with which 
it is found in different transcription and chromatin remodeling factors; MBD, Methyl CpG-
Binding Domain; ET, Extra-Terminal domain. 
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1.1.4.3 Interaction between PHD zinc finger/bromodomain   
containing transcription factors and TRIP-Br proteins 
 
Various of PHD zinc finger- and/or bromordomain proteins including KRIP-1, TIF1α, 
SP140, CBP, p300, PCAF and STAF65γ have been shown to interact with multiple 
members of  the TRIP-Br protein family (TRIP-Br1, TRIP-Br2 and CDCA4)  in vitro 
and in vivo to regulate transcription (Watanabe-Fukunaga et al.,2005; Lai et al., 2007; 
Hirose et al., 2003; Hsu et al., 2001). The features and proposed functions of these 
proteins are summarized in Table 1.3. Deletion analysis reveals that amino acid 
residues 161-178 of TRIP-Br1 are critical for its interaction with the PHD zinc finger- 
and (or) bromodomain- containing proteins KRIP-1, TIF1α and SP140 (Hsu et al., 
2001). This region is highly conserved in the four mammalian TRIP-Br protein family 
members (TRIP-Br1, TRIP-Br2, RBT1, and CDCA4) and the Drosophila homologue 
TARA (Calgaro et al., 2002), and is predicted to adopt an α-helical structure proposed 
to serve as an interface for interacting with the PHD-bromodomain motif (Hsu et al., 
2001). 
 
To date, no post-translational modifications such as lysine acetylation or methylation 
(bi- or tri-methylation) have been reported on TRIP-Br proteins. However, it is 
common for a modification-specific binding module to display functional plasticity. 
PTB domains, for instance, recognize both phosphorylated and non-phosphorylated 
motifs (Schlessinger and Lemmon, 2003). Chromodomains display the ability to bind 
RNA and methyllysine motifs and 14-3-3 proteins are able to interact with atypical 
sites that are not phosphorylated (Seimiya et al., 2000). The bromodomains of KRIP-1, 
CBP, P300, SP140, TIF1α, PCAF and STAF65γ are likely to mediate additional 
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protein-protein interactions with TRIP-Br proteins that do not involve acetylated 
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Table1.3: PHD zinc finger- and/or bromodomain-containing proteins that are 






Features TRIP-Br  
Protein(s) 
Interactors   














(Lai et al., 2007; Hsu 
et al., 2001)
 
A universal corepressor protein for the 
KRAB zinc finger- protein (KRAB-
ZFP) superfamily. KRIP-1 Assembles 
heterochromatin protein 1 (HP1), 
histone methyltransferase SETDB1 
and Mi-2 via PHD-bromodomain onto 
KRAB-ZFPs to coordinate the 
deacetylation and methylation of 
histones, resulting in heritable gene 












(Hsu et al., 2001)
 
Transcriptional coactivators or 
corepressors, depending on their 
interaction with transcription factors in 
response to different cellular signals, 
stressors or viral infections. 
Intrinsic HAT activity that acetylates 
histones and transcription factors. 
















Fukunaga et al.,2005; 
Lai et al., 2007; Hirose 
et al., 2003; Hsu et al., 
2001)
 
Structurally similar to p300 but 
functionally non-overlapping. 
Embryonic lethality of mice 
nullizygous for p300 or double 
heterozygous for p300 and CBP 
















(Hsu et al., 2001)
 
Transcriptional regulator of nuclear 
receptors shown to interact with 
numerous proteins involved in 












(Hsu et al., 2001)
 
Novel component of the nuclear body. 
May be involved in the regulation of 












(Lai et al., 2007)
 
Functions as HAT activity to promote 
transcriptional activation. Inhibits cell-
cycle progression and counteracts the 
mitogenic activity of the adenoviral 









(Lai et al., 2007)
 
Presumably functions in transcriptional 
regulation  (Martinez et al., 2001)
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1.1.4.4 Biological significance of the interaction between PHD zinc  
finger/bromodomain proteins and TRIP-Br proteins 
 
Mammalian TRIP-Br proteins (TRIP-Br1, TRIP-Br2 and RBT1) are able to stimulate 
the transcription activity of E2F1/DP1 complex (Darwish et al., 2007; Hsu et al., 
2001). Co-expression of PHD zinc finger- and bromodomain-containing protein 
KRIP-1 potentiates the ability of TRIP-Br proteins to co-activate E2F1/DP1 (Darwish 
et al., 2007; Hsu et al., 2001). Truncated version of KRIP-1, in which RING finger-B 
box-coiled coil (RBCC) tripartite motif and the PHD-bromodomain were deleted, 
lacked co-activation function, suggesting that the ability of KRIP-1 to interact with 
TRIP-Br proteins and/or its co-activation function is mediated through the 
evolutionarily conserved RBCC tripartite motif and/or the composite PHD 
bromodomain (Darwish et al., 2007; Hsu et al., 2001). pRB, as a major cell cycle 
regulator, is able to arrest cells in the G1 phase through interaction with E2F1–4. The 
co-expression of pRB is associated with repression of E2F1/DP1 transcriptional 
activity as well as TRIP-Br/KRIP-1 co-activation while a pRB mutant unable to bind 
to E2F1 is less able to repress the co-activation function of ectopically expressed 
TRIP-1 and KRIP-1 (Darwish et al., 2007; Hsu et al., 2001). The pRB mediated 
repression can be reversed in the presence of the E1A oncoprotein, a protein that 
binds to and sequesters pRB from E2F1. These results strongly suggest that the TRIP-
Br proteins function to integrate regulatory signals conveyed by PHD zinc finger- 
and/or bromodomain-containing proteins through direct functional interaction with 
transcription complexes assembled on E2F1-responsive promoters. 
 
The regulatory signal conveyed by PHD-bromodomain containing proteins to the 
E2F1/DP1 transcriptional machinery through TRIP-Br proteins appears to be crucial 
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for cell cycle progression since synthetic decoy peptides designed to antagonize the 
interaction between PHD zinc finger- and/or bromodomain-containing proteins and 
TRIP-Br1 or TRIP-Br2 elicit a state of global cell cycle arrest characterized by the 
suppression of DNA synthesis and cellular proliferation, DNA fragmentation through 
a cyclin E-dependent pathway involved in the maintenance of genomic stability, and 
cell death in U2OS cell (Sim et al., 2004).  Both the TRIP-Br1 and TRIP-Br2 decoy 
peptides are found to differentially down-regulate the expression of a subset of 
endogenous E2F1-responsive genes including FBW7, cdc2, DHFR and DNA 
polymerase α in vivo (Sim et al., 2004). Thus, the interaction between TRIP-Br 
proteins and PHD zinc finger- and/or bromodomain-containing proteins is required 
for proper execution of E2F1-dependent mammalian cell cycle progression.  
 
1.1.5    TRIP-Br1 is a CDK4-interacting protein 
 
TRIP-Br1 interacts with CDK4 but not CDK6, although CDK6 shares a high degree 
of homology with CDK4 (Sugimoto et al., 2002; Sugimoto et al., 1999). The binding 
region of TRIP-Br1 with CDK4 has been mapped to residues 44-161 of TRIP-Br1, 
which contain a proline-rich sequence (PEST). Notably, this region partially overlaps 
the SERTA motif (residues 38-85), the most highly conserved motif across all 
members of the TRIP-Br protein family. 
 
Addition of TRIP-Br1 to cyclin D1 and CDK4 has a small stimulatory effect on cyclin 
D1–CDK4 binding, whereas increasing amounts of p16INK4a effectively blocks the 
cyclin D1–CDK4 interaction (Sugimoto et al., 1999). In the presence of p16INK4a, 
forced expression of TRIP-Br1 protein stabilizes formation of an active cyclin D1–
CDK4- p16INK4a-TRIP-Br1 quaternary complex under low serum condition, while no 
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detectable cyclin D1–CDK4 complex formation is observed under low serum 
conditions in control cells despite high expression levels of both cyclin D1 and CDK4 
protein in the control cells (Sugimoto et al., 2002). Furthermore, treatment of the 
human primary fibroblasts TIG-3 cells with antisense oligomers against the TRIP-Br1 
gene significantly attenuates the cyclin D1–CDK4 complex formation and inhibits S-
phase entry (Sugimoto et al., 1999). This suggests that TRIP-Br1 may facilitate the 
formation of enzymatically active cyclin D–CDK complexes in the face of inhibitory 
levels of p16INK4a proteins through the formation of a cyclin D1–CDK4- p16INK4a-
TRIP-Br1 quaternary complex (Sugimoto et al., 1999).  
 
1.1.6    TRIP-Br proteins interact with cyclin A 
Both TRIP-Br1 and TRIP-Br2 are able to interact with cyclin A in vitro and in vivo, 
shown by GST binding and co-immunoprecipitation assays (S.I. Hsu, unpublished 
data).  The putative cyclin A binding site of TRIP-Br1/2 is conserved among all the 
TRIP-Br family members. Cyclin A is a key regulatory protein that is involved in 
both the S phase and the G2/M transitions of the mammalian cell cycle through its 
association with distinct CDKs (Desdouets et al., 1995; Pagano et al., 1992). At the 
G1/S check point of the cell cycle, cyclin A associates with CDK2 to coordinate the 
progression through S phase.  During late S and early G2-M, the cyclin A-cdc2 complex 
binds E2F1-3 family members and phosphorylates E2F1 and DP1 subunits to inhibit the 
ability of E2F1/DP1 dimer to bind DNA (Woo and Poon, 2003). This contributes to the 
down-regulation of E2F1 activity required for cells to exit S phase (Woo and Poon, 2003). 
The biological significance of TRIP-Br1-cyclin A interaction is currently still unknown. It 
is possible that TRIP-Br proteins may serve as regulatory substrates for phosphorylation 
by cyclin A dependent kinases.  
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1.1.7    TRIP-Br proteins are novel cell cycle regulators 
 
Several lines of evidence support the proposal that TRIP-Br family members 
functional physiologically as novel cell cycle regulators. First of all, all members of 
the mammalian TRIP-Br family (TRIP-Br1, TRIP-Br1, RBT and CDCA4) possess the 
unique ability to modulate the transcriptional activity of the E2F1/DP1 machinery 
(Darwish et al., 2007; Hayashi et al., 2006; Hsu et al., 2001). TRIP-Br1, TRIP-Br2 
and RBT substantially stimulate E2F1/DP1 transcription while CDCA4 inhibits 
E2F1/DP1 transcriptional activity. The direct physical contact between TRIP-Br 
proteins and the E2F1/DP1 complex has been demonstrated in two members of 
mammalian TRIP-Br family (TRIP-Br1 and TRIP-Br2) (Hsu et al., 2001). Second, 
multiple members of the mammalian TRIP-Br family (TRIP-Br1, TRIP-Br1 and 
CDCA4) bind to PHD zinc finger- and/or bromodomain-containing proteins, a group 
of transcription factors that play pivotal roles in chromatin-remodeling and 
transcriptional regulation (Blom et al., 1999; Hirose et al., 2003; Hsu et al., 2001; Lai 
et al., 2007). Antagonizing the interaction between TRIP-Br proteins and PHD zinc 
finger/bromodomain containing transcription factors by synthetic decoy peptides 
leads to the suppression of DNA synthesis and global cell growth arrest (Sim et al., 
2004). Thirdly, TRIP-Br1 interacts with CDK4 directly. The presence of TRIP-Br1 
render the cyclin D1-CDK4 complex resistant to the inhibitory effect of p16INK4a, 
resulting in an active cyclin D1-CDK4- p16INK4a-TRIP-Br1 quaternary complex 
(Sugimoto et al., 1999). Fourth, both TRIP-Br1 and TRIP-Br2 are able to interact with 
cyclin A in vitro and in vivo via the conserved cyclin A binding motif, presumably 
serving as the substrates of cyclin A-CDK2 serine-threonine kinase [S.I. Hsu, 
unpublished data and (Hsu et al., 2001; Sugimoto et al., 2002)]. Fifth, a fluctuating 
protein expression pattern during different phases of the cell cycle is noted for TRIP-
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Br1 in a human cancer cell line as well as human primary fibroblasts cells.  U2OS 
cells released from M-phase block and TIG3 human primary fibroblasts released from 
serum startavation exhibit a biphasic expression pattern of TRIP-Br1, with increased 
expression in mid-G1, transient decreased expression during late G1, and high 
expression levels upon entry and throughout S phase (Hsu et al., 2001; Sugimoto et al., 
2002). One of the two RBT1 transcript variants is tightly regulated throughout the G1 
and S phases of the cell cycle. The pattern of expression is identical to that of TRIP-
Br1 (Darwish et al., 2007). CDCA4 expression is induced as cells traverse the G1/S 
checkpoint of the cell cycle (Hayashi et al., 2006). All these observations are 
consistent with the proposed function of TRIP-Br proteins as a novel family of cell 
cycle regulators. 
 
1.1.8   The integrator model of TRIP-Br protein function in 
cell cycle regulation  
 
TRIP-Br1 and TRIP-Br2 have been shown to make direct physical contact with 
protein components of two key cell cycle regulatory protein complexes that promote 
sequential cell cycle progress from late G1 through the G1/S checkpoint and traversal 
of S phase to the S/G2 boundary (and likely beyond):  1) cyclin D1/CDK4/p16INK4a; 
and 2) E2F1/DP1/RB (Hsu et al., 2001; Sugimoto et al., 2002). The unique ability of 
these TRIP-Br family members to interact with PHD zinc finger- and/or 
bromodomain-containing transcriptional regulators such as KRIP, CBP and p300 and 
with cyclin A-containing cyclin/CDK complexes further contribute to regulation of 
E2F1/DP1 mediated gene transcription and cell cycle progression (Blom et al., 1999; 
Hirose et al., 2003; Hsu et al., 2001; Lai et al., 2007). Given that the E2F1 
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transcription factors promote traversal of the G1/S transition and that E2F1 plays a 
role in the regulation of cell proliferation, Hsu et al have proposed an “integrator” 
model in which it is envisioned that at least a subset of TRIP-Br proteins function 
physiologically as integrators of stimulatory or inhibitory growth signals conveyed by 
PHD zinc finger- and/or bromodomain-containing proteins on E2F1-responsive 
promoters in a manner that contributes to the regulation of E2F1/DP1 transcription 
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Figure 1.4: The integrator model of TRIP-Br protein function. 
 
In response to mitogenic stimulation and in the presence of TRIP-Br1 (step 1), cyclin 
D associates with CDK4 simultaneously with p16INK4a (step 2) to form a functionally 
active quaternary complex. This complex contributes both to cyclin D-CDK4 
activation and hypo-phosphorylation of pRB as well as to activate cyclin E-CDK2 
(step 3). The hypo-phosphorylated pRB bound to transcriptionally inactive E2F1/DP1 
complexes serves as a target of cyclin E-CDK2 mediated hyper-phosphorylation (step 
4), resulting in the dissociation of pRB and release of cells from the late G1 
checkpoint. Upon pRB dissociation, TRIP-Br1 is recruited to the E2F1/DP1 
complexes on E2F1-responsive promoters through physical association with DP1 
(step 5), resulting in the assembly of an E2F1/DP1/TRIP-Br1 ternary complex. PHD 
zinc finger- and/or bromodomain-containing proteins such as p300/CBP and KRIP-1 
compete for binding to TRIP-Br proteins and confer positive (+) or negative (-) 
regulatory signals to E2F1/DP1 transcription complexes assembled on E2F1-
responsive promoters (step 6). An “integrated” transcriptional read-out is achieved by 
effects on the basal transcriptional machinery. (Figure modified from: Hsu et al., 2001) 
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1.2     TRIP-Br proteins and cancer 
 
1.2.1  TRIP-Br1 and RBT1 are localized at 19q13, a common 
amplicon in human cancer 
 
Gene amplification, which usually results in the overexpression of an oncogene, is 
one of the common genetic alterations in various solid tumors, probably because the 
overexpression of an oncogene confers a growth advantage. Two members of the 
TRIP-Br gene family, TRIP-Br1 and RBT1, are closely localized at chromosome 
19q13. Amplification of chromosome 19q13 has been linked to different types of 
cancers including pancreatic carcinoma (Curtis et al., 1998; Hoglund et al., 1998; 
Miwa et al., 1996), ovarian carcinoma (Bicher et al., 1997; Thompson et al., 1996; 
Wang et al., 1999), breast cancer (Muleris et al., 1995) and lung cancers (Marchio et 
al., 1997; Petersen et al., 1997), suggesting that genes included in this amplicon may 
participate in tumor formation. Indeed, cytogenetic studies reveal a gain of 19q13 in 
12/31 (39%) of primary ovarian cancers. Amplification and overexpression of the 
TRIP-Br1 gene is found in 4 of 4 ovarian cancer cell lines studied (Tang et al., 2005; 
Tang et al., 2002). Moreover, overexpression of the TRIP-Br1 protein is detected in 
49% of invasive ovarian carcinoma (Tang et al, 2005). RBT1 mRNA expression is 
significantly higher in human breast adenocarcinoma cell lines MCF7 and ZR-75, 
human osteosarcoma cell line SaOS-2 and human non-small cell lung cancer cell line 
H661, compared to the normal non-immortalized human mammary epithelial cells 
and normal non-immortalized human bronchial epithelial cells (Cho et al., 2000). 
These observations strongly support that TRIP-Br1 and RBT1 may be biological 
targets of an amplification event at 19q13.1 in human cancer and therefore play 
important roles in tumorigenesis. 
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1.2. 2  TRIP-Br proteins promote cell growth 
  
Increasing evidence supports a model in which TRIP-Br proteins (TRIP-Br1, TRIP-
Br2 and RBT1) function physiologically as potent cell growth promoting factors. 
Ectopic expression of human TRIP-Br1 is able to substitute for growth factors to 
sustain cell proliferation of non-transformed rat fibroblasts in 1% serum containing 
medium (Sugimoto et al., 1999). Targeted knock-down of TRIP-Br1 or TRIP-Br2 by 
transfection of sequence-specific DNA enzymes in WI-38 normal human fibroblasts 
has been shown to disrupt mitogenic signaling in a manner that suppresses serum-
induced cyclin E expression, S-phase entry and cellular proliferation (Sim et al., 
2006). Primary mouse embryonic fibroblasts isolated from TRIP-Br2-/- animals 
exhibit a proliferative block characterized by reduced doubling time, colony 
formation and BrdU incorporation, as compared to wild type animals (Sim et al., 
2006). Silencing of TRIP-Br1 gene expression by small interfering RNA (siRNAs) in 
the ovarian cancer cell line SKOV3 inhibited cell growth as well as colony formation 
on soft agar (Tang et al., 2005).  In addition, silencing of RBT1 transcript expression 
by siRNA substantially reduced the cell growth of the human breast adenocarcinoma 
cell line MCF7 (Darwish et al., 2007). Similar inhibitory effect of RBT1 siRNA was 
shown on PANC-1 cell line, a pancreatic cancer cell line known to possess an 
amplicon on 19q13. (Darwish et al., 2007). The above phenotypes observed upon 
increasing or decreasing TRIP-Br expression are in agreement with the known 
functions of TRIP-Br proteins, providing strong support for the paradigm of TRIP-Br 
proteins as a family of pro-proliferative molecules that promote cell growth. Notably, 
despite the high sequence homology, it appears that there is no functional redundancy 
at the cellular level among the TRIP-Br family members since knocking down or 
knocking out even one member severely impairs normal cell growth and proliferation.    
Zhijiang Zang  Medicine, NUS 
PhD. Thesis  2003-2007 
    
               46
1.2.3    TRIP-Br proteins are a family of oncoprotein 
To date, two TRIP-Br family members (TRIP-Br1 and RBT1) have been reported to 
be oncogenes (Darwish et al., 2007; Tang et al., 2005). TRIP-Br2 has recently been 
demonstrated to be a third oncogene in this family by our group (J.K. Cheong et al, 
unpublished data). Stable NIH 3T3 cell lines and rat normal fibroblasts expressing 
TRIP-Br1 or TRIP-Br2 or RBT1 show anchorage-independent growth in vitro and 
tumor formation in nude mice, the classical hallmarks of a proto-oncogene (Darwish 
et al., 2007; Tang et al., 2005). Specific silencing of the TRIP-Br1 or TRIP-BR2 or 
RBT1 substantially decreases cancer cell growth (Darwish et al., 2007; Tang et al., 
2005). Moreover, consistent with the oncogenic potentials of these oncogenes, 
overexpression of TRIP-Br1 or TRIP-BR2 or RBT1 has been detected in a variety of 
human cancer tissues and human cancer cell lines, suggesting that TRIP-Br 
oncoproteins play a role in the human tumorigenesis (Table 1.4). The inappropriate 
activation of two key cell growth regulator complexes during G1/S cell progression, 
E2F1/DP1/RB and cyclin D/CDK4/p16INK4a may underlie the oncogenic mechanism 
of TRIP-Br proteins in human cancers. 
 
 
1.2.4   The integrator function of TRIP-Br proteins and 
cancer 
 
PHD zinc finger- and/or bromodomain-binding motif is one of the most conserved 
regions shared by all TRIP-Br protein family members. TRIP-Br proteins have been 
demonstrated to possess the unique ability to interact with PHD zinc finger- and/or 
bromodomain-containing proteins, a group of transcription factors that play crucial 
roles in chromatin remodeling and transcriptional regulation. These functional 
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protein-protein interactions have been implicated in the co-regulation of E2F1-
dependent transcription. The TRIP-Br proteins are proposed to serve as physiological 
integrator that recruit PHD zinc finger- and /or bromodomain-containing 
transcriptional regulators such as CBP, p300, and KRIP-1, which may potentially 
confer both positive and negative co-regulatory activity to E2F1/DP1 transcription 
complexes. Antagonizing the integrator function of TRIP-Br1 or TRIP-Br2 by 
Penetratin-tagged decoy peptides that mimic the PHD-bromodomain interacting 
regions of TRIP-Br1 or TRIP-Br2, results in repression of transcriptional activity of 
an artificial E2F1 responsive promoter, as well as inhibition of gene transcriptional 
activity of a subset of endogenous E2F1-responsive genes including FBW7, DHFR, 
DNA Polymerase α and CDC2 in human osteosarcoma U2OS cells (Sim et al., 2004).  
This suggests that the “integrator” function of TRIP-Br proteins is required for the 
proper execution of the transcriptional programs of these genes.   Exposure of cancer 
cell lines to either of the two decoy peptides designed to antagonize the “integrator” 
function of TRIP-Br proteins triggers strong anti-proliferative effects and caspase-3-
independent sub-diploidization (Sim et al., 2004). The observed effect of TRIP-Br 
decoy peptides on cancer cells in vitro suggests that the “integrator” function of 
TRIP-Br proteins may be a novel therapeutic target for the treatment of hyperplastic 











Zhijiang Zang  Medicine, NUS 
PhD. Thesis  2003-2007 
    
               48









Overexpression in Cancer Tissues 













in vitro and tumor 
formation in mice 
(Darwish et al., 
2007; Tang et al., 
2005). 
Overexpressed in 18% (3/17) of 
ovarian cystadenomas, 25% (3/12) 
of borderline ovarian tumors, and 
49% (102/209) of ovarian 
carcinomas shown by 
immunohistochemistry studies 
(Darwish et al., 2007; Tang et al., 
2005). 
 
Overexpression is correlated with 
the stage (FIGO stage) and grade 
(Silverberg grade) of ovarian cancer 
(Darwish et al., 2007; Tang et al., 
2005). 
  
An increase of 2-23 folds of TRIP-
Br1 expression in 39/39 human 
squamous cell carcinomas of head 
and neck relative to 11 normal 












in vitro and tumor 
formation in mice 
(J.K. Cheong et al, 
unpublished data) 
Overexpressed in prostate 
carcinoma, squamous cell lung 
carcinoma, lung adenocarcinoma, 
ovarian cystadenocarcinoma, 
colorectal carcinoma, renal cell 
carcinoma, osteosarcoma and 
hepatocellular carcinoma based on a 
tissue microarray using immuno-











in vitro and tumor 
formation in mice 
(Darwish et al., 
2007) 
RBT1 mRNA expression is 
significantly higher in human breast 
adenocarcinoma cell lines MCF7 
and ZR-75, human osteosarcoma 
cell line SaOS-2 and human non-
small cell lung cancer cell line 
H661, compared to the normal non-
immortalized human mammary 
epithelial cells and normal non-
immortalized human bronchial 
epithelial cells (Cho et al., 2000). 
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TRIP-Br proteins are a novel family of transcriptional co-regulators involved in E2F-
mediated cell cycle progression. Three of the four mammalian members of TRIP-Br 
family, including TRIP-Br1, TRIP-Br2 and RBT1, are known oncogenes. Our group 
has previously shown that antagonism of the TRIP-Br integrator function of TRIP-
Br1 or TRIP-Br2 using synthetic peptides which compete the interaction between 
TRIP-Br1/2 and PHD zinc finger/bromodomain-containing transcription factors, 
elicits strong anti-proliferative effects and caspase-3-independent sub-diploidization 
in U2OS human osteosarcoma cells through a mechanism involving altered 
expression of a subset of E2F1-responsive genes and loss of genomic stability. The 
physiological role of TRIP-Br proteins as cell growth promoting factors and the 
observed anti-proliferative effects of the TRIP-Br decoy peptides on cancer cells 
suggests that antagonism of the integrator function of TRIP-Br proteins may represent 
a novel transcription-based chemotherapeutic strategy for the treatment of cancers and 
other hyperplastic lesions such as psoriasis. Appropriate targets for such novel 
peptide-based therapy are envisioned to include cutaneous and intracavitary 
superficial mucosal lesions such as vulvar intraepithelial neoplasia, cervical dysplasia 
or carcinoma in situ, oral cancer and nasopharyngeal bladder cavity mucosal surfaces, 
all of which are known to ubiquitously express TRIP-Br family members.   The 
objectives of this study include: 
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a) Proof-of-principal studies of the integrator function of TRIP-Br transcription factor 
as therapeutic drug target for the treatment of human cutaneous and intracavitary 
superficial lesion. 
 
b) Elucidation of novel regulation pathway of TRIP-Br proto-oncoprotein in 
mammalian cells by identifying protein-protein interactors of TRIP-Br1 and 
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CHAPER THREE 
 
EVALUATION OF THE TRIP-BR PROTEINS AS 
CHEMOTHERAPEUTIC DRUG TARGET IN HUMAN 




2.1   Introduction 
 
TRIP-Br1 (p34SEI-1, SEI-1) and TRIP-Br2 (SEI-2) are important cell cycle regulators 
that function at E2F1-responsive promoters to integrate signals provided by PHD zinc 
finger- and/or bromodomain-containing proteins such as CBP/p300 and KRIP-1 (Hsu 
et al., 2001; Sugimoto et al., 1999; Watanabe-Fukunaga et al., 2005).  TRIP-Br1 
interacts with CDK4 and renders the cyclin D1-CDK4 complex resistant to the 
inhibitory effects of p16INK4a, a tumor suppressor gene that functions physiologically 
to inactivate the cyclin D1-CDK4 complex (Sugimoto et al., 1999).  The fact that 
ectopic expression of human TRIP-Br1 (hTRIP-Br1) induces rat fibroblasts to 
proliferate in “serum-free medium (1% serum),” and the observation that primary 
mouse embryonic fibroblasts (PMEFs) derived from TRIP-Br2-/- mice exhibits a 
significant proliferative block strongly suggest that TRIP-Br proteins are potent cell 
growth promoting factors (Sim et al., 2006).  Similar to other major components of 
the cyclin D1/CDK4/p16INK4 and E2F1/DP1/RB regulatory pathways of cell cycle 
progression, increasing evidences continue to emerge demonstrating that abnormal 
overexpression of TRIP-Br proteins are also associated with tumorigenesis (Gladden 
and Diehl, 2005; Tang et al., 2002; Zhu, 2005).  It was recently demonstrated that 
stable overexpression of TRIP-Br1 in NIH 3T3 mouse fibroblast cells results in 
anchorage-independent cell growth in vitro and tumor formation in nude mice (Tang 
et al., 2005). Overexpression of the TRIP-Br1 protein was observed in 49% of 
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invasive ovarian carcinomas (Tang et al., 2005).  In addition, an increase of 2-23 fold 
in the expression of TRIP-Br1 has been observed in 39/39 of human squamous cell 
carcinomas of head and neck relative to the expression of TRIP-Br1 in 11 normal 
specimens (Li et al., 2005). These studies strongly implicate an important role for 
TRIP-Br proteins in cell cycle regulation and tumorigenesis.  
 
Our group has previously shown that antagonism of the TRIP-Br integrator function 
of TRIP-Br1 or TRIP-Br2 using synthetic peptides which compete the interaction 
between TRIP-Br1/2 and PHD zinc finger/bromodomain-containing transcription 
factors, elicits strong anti-proliferative effects and caspase-3-independent sub-
diploidization in U2OS human osteosarcoma cells through a mechanism involving 
altered expression of a subset of E2F1-responsive genes and loss of genomic stability  
(Sim et al, 2004, Sim et al, 2006). The physiological role of TRIP-Br proteins as cell 
growth promoting factors and the observed anti-proliferative effects of the TRIP-Br 
decoy peptides on cancer cells suggests that antagonism of the integrator function of 
TRIP-Br proteins may represent a novel transcription-based chemotherapeutic 
strategy for the treatment of cancers and other hyperplastic lesions such as psoriasis 
(Sim et al., 2004). Appropriate targets for such novel peptide-based therapy are 
envisioned to include cutaneous and intracavitary superficial mucosal lesions such as 
vulvar intraepithelial neoplasia, cervical dysplasia or carcinoma in situ, oral cancer 
and nasopharyngeal bladder cavity mucosal surfaces, all of which are known to 
ubiquitously express TRIP-Br family members.  In the present study, we performed 
pre-clinical proof-of-principle studies of the efficacy of Penetratin-tagged decoy 
peptides as antagonists of the integrator function of TRIP-Br1 and TRIP-Br2 in 3 
cancer cell lines (human nasopharyngeal cancer cell line CNE2, human cervical 
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cancer cell line Ca Ski and human melanoma cell line MeWo) both in vitro and in 
vivo. The decoy peptide sequences corresponding to the minimal PHD-bromodomain 
interacting region of TRIP-Br1 and TRIP-Br2 were synthesized.  To mimic the 
superficial growth pattern of cutaneous/mucosal (e.g. skin cancer, psoriasis, warts) 
and intracavitary lesions (e.g. cervical cancer, nasopharyngeal carcinoma, oral 
cancer), a chick embryo chorioallantoic membrane (CAM) tumor xenograft model 



































Zhijiang Zang  Medicine, NUS 
PhD. Thesis  2003-2007 
    
               54
2.2      Materials and Methods 
2.2.1    Materials 
2.2.1.1   Decoy peptide 
TRIP-Br1 and TRIP-Br2 decoy peptides have been previously described (Sim et al., 
2004). Peptide sequences corresponding to the minimal PHD-bromodomain 
interacting region of TRIP-Br1 and TRIP-Br2 were synthesized by Biopeptide 
Company (San Diego, CA).  A “scrambled peptide” was used as a negative control. 
The Penetratin tag sequence (underlined) was synthesized at the N-terminus to 
facilitate cellular internalization. For in vitro and in vivo peptide uptake experiments, 
the carboxyfluorescein-labeled peptides were used.  All peptides were dissolved in 






2.2.1.2  Cell culture 
Human nasopharyngeal cancer CNE2 cells were a kind gift from Dr. Tao (John’s 
Hopkins, Singapore).  The human cervical cancer Ca Ski and the human melanoma 
MeWo cell lines were purchased from ATCC (Manassas, VA).  Cells were grown in 
RPMI (CNE2 and Ca Ski) or DMEM (MeWo) supplemented with 10% fetal calf 
serum and 100 U/ml penicillin and streptomycin at 37ºC in humidified 5% CO2 
incubators.  Ca Ski cell growth medium was further supplemented with 2 mM L-
glutamine, 1.5 g/L sodium bicarbonate and 1.0 mM sodium pyruvate.    
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2.2.2   Method  
2.2.2.1 Generation and characterization of monoclonal and 
polyclonal   antibodies against hTRIP-Br proteins 
 
Generation of mouse monoclonal antibodies against 2 short peptide sequences of 
hTRIP-Br1 was employed because of the high degree of sequence homology between 
mouse and human TRIP-Br1.  These peptide sequences were chosen on the basis of 
their antigenicity, hydrophilicity and accessibility as identified through software tools 
from Alpha Diagnostic International, Inc. (http://www.4adi.com).  Monoclonal 
antibody TB1-27#2 specific for hTRIP-Br1 was generated to a 16 amino acid N-
terminal sequence of TRIP-Br1 (DPGHAAVAQAPPAVAS) in which mouse and 
human TRIP-Br1 differ by only 4 non-contiguous amino acids, using the ClonaCell-
HY Hybridoma Cloning Kit (StemCell Technologies).  Rabbit polyclonal antibodies 
were generated against a 15 amino acid N-terminal sequence of human TRIP-Br2 
(MLGKGGKRKFDEHED). Specificity of the above antibodies for TRIP-Br proteins 
was confirmed by Western blot analyses and immunoprecipitation.   
 
2.2.2.2   Western blot for detection of TRIP-Br expression 
Sub-confluent CNE2, MeWo and Ca Ski cells were used to prepare total cell lysates 
using 4% SDS.  Total cell lysates were quantitated and resolved by SDS-PAGE and 
transferred to a PVDV membrane (Immobilon-P, Millipore, Billerica, MA).  
Immunoblotting was performed with mouse anti-human TRIP-Br1 monoclonal 
antibody TB1-27-2 and rabbit anti-human TRIP-Br2 polyclonal antibody.  
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2.2.2.3 In vitro and in vivo decoy peptide uptake assay by flow     
cytometric analysis and confocal microscopy 
 
 For in vitro assays, MeWo cells were treated with FITC-*Br2 (25 uM) for 3 hours,  
fixed with 2% paraformaldehyde and followed by 70% ethanol/PBS for flow 
cytometric analysis (Beckman Coulter, Epics Altra, PMT1: 488 nm, FITC: 525 nm).  
The cells was spun down and resuspended in DAPI/VectorShield® (H-1200, Vector 
laboratories,, Burlingame, CA) at 1:1 ratio in 20 µl.  The stained cells were mounted 
on cover slips for confocal microscopy (Olympus Fluoview 500, FV500, model 1×81, 
FITC:  488 nm; emission filter for FITC: BA505 1F, DAPI: 405 nm; emission filter 
for DAPI: BA430-460).  For in vivo assays, Ca Ski-derived chick CAM tumor 
xenografts were treated with 200 µl of topical applied FITC-*Br2 (25 µM) for 4 hours 
prior to confocal microscopy and flow cytometric analysis.  
 
2.2.2.4   Cell cycle analysis 
CNE2, Ca Ski or MeWo cells were grown on 6-well plates and plated at 3×104, 
10×104 and 3×104 cells/well, respectively, 24 hours before transfection.  Cells were 
exposed to 50 µM *Br1, *Br2, *Scr, or 0.2% DMSO for 48 hours and then fixed with 
70% ethanol/PBS and stained with 200 µl/ml RNase A and 20 µg/ml of PI at 37°C for 
30 minutes before flow cytometric analysis (PI:  610 nm).  
 
2.2.2.5   BrdU incorporation assay   
CNE2, Ca Ski or MeWo cells were plated at 500, 3000 and 3000 cells/well, 
respectively, on 96-well plates for 24 hours before transfection.  Cells were treated 
with 10, 50 or 100 µM of *Br1, *Br2, *Scr, or 0.2% DMSO for 72 hours.  
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Bromodeoxyuridine (BrdU) incorporation was monitored with a colorimetric ELISA 
assay using a cell proliferation kit according to manufacturer’s recommendations 
(Boehringer Mannheim, Mannheim, Germany).  
 
2.2.2.6  Colony formation assay 
CNE2, Ca Ski or MeWo cells were plated at 5×103, 2×104 and 2×104 cells/well, 
respectively, on 24-well plates for 24 hours before transfection.  Cells were exposed 
to 50 µM of *Br1, *Br2, *Scr, or 0.2% DMSO for 4 hours and then fixed with 100% 
methanol, stained with 0.4% giemsa stain for 30 min and rinsed with water.  For 
colony quantitation, the stain was released by treatment with 1% SDS and quantitated 
by spectrophotometry at OD595. 
 
2.2.2.7  Generation of nude mouse tumor xenograft models 
Human nasopharyngeal and cervical tumor xenograft models were generated by 
subcutaneous injection of cancer cells (2×105 cells/mouse for CNE2, 5×105 
cells/mouse for Ca Ski) in 50 µl of blank RPMI medium into the flanks of BALB/C 
nude mice (5-6 weeks).  A mouse orthotopic human melanoma xenograft model was 
produced by intradermal injection of MeWo cells (5×105 cells/mouse) to the flank of 
the mouse.  All animal work was approved by the Animal Care and Use Committee of 
the National University of Singapore. 
 
2.2.2.8 Chick embryo chorioallantoic membrane (CAM) tumor 
xenograft model establishment and validation 
 
 The chick CAM model protocol used was modified from Dani et al (Dani and 
Espindola, 2002).  Briefly, a 2 cm diameter round window on the flat pole of the 
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eggshell was created by cutting through the eggshell without damaging the outer shell 
membrane using an electric drill on day 9 of incubation.  On day 10, the window was 
opened and the outer and inner shell membranes were gently removed to expose the 
underlying CAM.  Special care was taken to avoid puncturing the CAM when peeling 
off the inner shell membrane.  The CAM was gently traumatized by laying a 1-cm 
wide strip of lens tissue over it and then peeling it off.  Tumor cells (1×106 cells/egg 
for CNE2 and 3×106 cells/egg for Ca Ski and MeWo cell lines in 50 µl of blank RPMI 
medium) were inoculated directly onto the traumatized CAM.  The shell window was 
covered with a 35 mm sterile tissue culture dish, sealed with scotch tape and returned 
to the incubator.  The embryo was incubated until day 17 with daily monitoring and 
terminated by hypothermia. Tumors were harvested and fixed in 10% formalin for 
H&E staining.  Single cell suspensions of primary cancer cells derived from chick 
embryo CAM tumor xenografts were generated by mechanical dissection followed by 
trypsin digestion for 8 minutes.  The morphology of these primary tumor cells was 
observed and compared with that of the tissue culture-derived cells used for chick 
embryo CAM tumor inoculation under phase contrast microscopy.  
 
2.2.2.9 In vivo effect of peptide treatment on tumor growth using 
the chick CAM model 
 
CNE2-, Ca Ski- and MeWo-derived tumor xenograft models were generated as 
described in Sections 2.2.2.7 and 2.2.2.8.  Treatment of tumors growing on the surface 
of the chick embryo CAM was initiated on day 12 (2 days after cancer cell 
inoculation).  Established tumors were treated with 50 µl of *Br1, *Br2, *Scr or 0.2% 
DMSO vehicle control in 200 µl of sterile PBS by topical administration of the 
peptides directly onto the tumor xenografts on the chick embryo CAM.  Treatment 
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was administered on a daily basis.  On day 17 of incubation, the embryos were 
terminated and the xenografts were harvested and weighed.  Each treatment group 
included 4 chick embryos and the experiments for each model were repeated at least 
two (CNE2-derived model) or three times (Ca Ski- and MeWo-derived model). To 
evaluate the effect of the higher dosage of *Br1 on the MeWo-derived melanoma 
chick CAM model, 50, 100 and 200 µl of *Br1 or *Scr were used to treat the tumor 
xenografts.  The experiments were performed three times with four chick embryos in 
each treatment group. 
 
2.2.2.10  Statistical analysis 
The weights of the peptide-treated tumor xenografts derived from each model were 
analyzed by SPSS (12.0).  The mean tumor weight for each group was calculated by 
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2.3       Results 
2.3.1    TRIP-Br decoy peptides inhibit the proliferation of CNE2,    
Ca Ski and MeWo cells in vitro 
 
The TRIP-Br decoy peptides have been shown to perturb the interactions between 
TRIP-Br proteins and the PHD zinc finger- and/or bromodomain-containing 
mammalian transcription factor, KRIP-1, in vitro. It was further shown that the ability 
of KRIP-1 to co-activate TRIP-Br transcriptional activity in the cell-based luciferase 
assay was abrogated, following treatment with TRIP-Br decoy peptides (Sim et al., 
2004). The anti-proliferative effect of the TRIP-Br decoy peptides was tested on 
human nasopharyngeal cancer (CNE2), cervical cancer (Ca Ski) and melanoma 
(MeWo) cancer cell lines in vitro.  The expression of TRIP-Br1 and TRIP-Br2 in 
these three cell lines was confirmed by Western blot analysis (Figure 2.1). As 
expected, both TRIP-Br1 and TRIP-Br2 proteins are abundantly expressed in these 
representative cancer cell lines.  The efficiency of cellular uptake of decoy peptides 
was determined by treatment with 25 µM FITC-labeled TRIP-Br decoy peptides or 
scrambled peptide for 3 hours followed by confocal microscopy and flow cytometric 
analysis.  Both methods demonstrated that up to 97-99% of the cells were FITC 
positive, confirming the efficient cellular uptake of each of the Penetratin-tagged 
decoy peptides (data not shown).  PI staining followed by cell cycle analysis using 
flow cytometry showed that treatment with 50 µM of TRIP-Br1 (*Br1) and TRIP-Br 
2 (*Br2) decoy peptides, but not the scrambled decoy peptide (*Scr) for 48 hours, 
may significantly induce subdiploidization and cell death, as evident by an increased 
sub-G1 population (Figure 2.2A).  When cancer cells were treated with an increasing 
dosage of decoy peptides (10 µM, 50 µM, 100 µM) for 72 hours, DNA synthesis by 
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*Br1- and *Br2-treated cells was decreased in a dose-dependent manner as reflected 
by a decreased BrdU incorporation, while that of *Scr-treated cells was not 
significantly altered (Figure 2.2B).  The anti-proliferative effect of TRIP-Br decoy 
peptides was further validated by a colony formation assay.  The ability of cancer 
cells to form colonies in tissue culture after exposure to 50 µM of *Br1, *Br2 or *Scr 
peptides for 4 days was estimated by Giemsa staining followed by colorimetric 
quantitation.  The results showed that the ability of *Br1 and *Br2 treated cells to 
form colonies was decreased by approximately 55% and 80%, respectively (Figure 
2.2C).  The results of the above in vitro proliferation assays are consistent with our 
previous observation in U2OS cells (Sim et al., 2004), thus demonstrating that 
antagonism of the integrator function of TRIP-Br proteins expressed in CNE2, Ca Ski, 
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Figure 2.1:  Endogenous TRIP-Br1 and TRIP-Br2 protein expression 
in representative human cancer cell lines detected by Western blot 
analysis.  
 
Each lane was loaded with 50 µg of total cell lysate prepared in 1X SDS sample 
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Figure 2.2:  In vitro evaluation of the effect of exposure to TRIP-Br 
decoy peptides.  
 
Controls are no treatment (No Tx), DMSO vehicle alone and scramble peptide (*Scr).  
A) Cell cycle analysis by PI staining after treatment with 50 µM decoy peptide for 48 
hours. The sub-G1 population was dramatically increased after TRIP-Br decoy peptide 
exposure, suggesting cell-death following antagonism of the TRIP-Br integrator 
function.  B) BrdU incorporation assay showing dose-dependent inhibition of DNA 
synthesis after treatment with various concentrations of decoy peptides for 72 hours.  
C) Colony formation assay showing inhibition of colony forming potential of cells 
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2.3.2 Tumors xenografts in the chick embryo CAM model are    
accessible to the topically applied decoy peptide treatment 
 
To select an appropriate model for the assessment of the effect of TRIP-Br decoy 
peptides on tumor growth in vivo, we compared the traditional nude mouse xenograft 
model with a recently-described chick embryo CAM model (Dani and Espindola, 
2002). Since no orthotopic human nasopharyngeal cancer or cervical cancer mouse 
models have been reported, we generated novel mouse tumor models by subcutaneous 
injection of CNE2 and Ca Ski cells.  All cancer cell inoculations gave rise to visible 
tumors (data not shown).  The chick embryo CAM model was generated using a 
modified protocol (refer to Section 2.2.2.8) to achieve greater consistency in cancer 
cell inoculation and to facilitate the daily application of decoy peptide treatment.  All 
of the eggs formed superficial visible tumors after inoculation of 1×106 CNE2 
cells/egg on the chick embryo CAM.  Typical xenogrft growth kinetics on chick 
embryo CAM after topical inoculation of MeWo cells is shown in Figure 2.3A. 
Primary tumor cell suspensions prepared from Ca Ski-derived cervical tumors and 
MeWo-derived melanomas grown on chick embryo CAM retained the same cell 
morphology as that of the original tissue culture cells used for inoculation (Figure 
2.3B).  H&E staining of the CAM xenografts confirmed the malignant status of the 
tumor xenografts.  In the nude mouse subcutaneous tumor model, all tumors that 
developed were covered by a full skin layer, rendering the model unsuitable for the 
evaluation of topically-applied compounds.  In an orthotopic human melanoma 
xenograft model produced by intradermal injection of MeWo cells to the nude mouse, 
HE staining of the tumor tissue further demonstrated that the “superficial tumor” that 
arose also contains keratin, epidermis and dermis on the top of the tumor tissue 
(Figure 2.4A). 
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 In contrast, tumors generated on the chick embryo CAM model grew superficially 
and were accessible to topically-administered drug (Figure 2.4A), as evident by 
confocal microscopy and flow cytometric analysis of single cell suspensions prepared 
from Ca Ski tumor grown on chick embryo CAM that had been topically treated with 
25 µM FITC-*Br2 for 4 hours.  Confocal microscopy revealed that topically applied 
FITC-labeled peptides were present in the cytoplasm as well as nucleus of tumor cells 
(Figure 2.4B).  Approximately 45% of tumor cells were FITC positive after in vivo 
exposure for 4 hours to topically applied peptides in 3 independent experiments 















Zhijiang Zang  Medicine, NUS 
PhD. Thesis  2003-2007 
    
               66
 
 
Figure 2.3: Chick embryo chorioallantoic membrane (CAM) cancer 
model validation. 
 
 A) Typical tumor growth of cancer cells on chick embryo CAM after topical 
inoculation of 3×106 MeWo cells following gentle traumatization of embryo CAM. B) 
The primary cancer cells derived from a tumor in the chick CAM model had the same 
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Figure 2.4:  Comparison of nude mouse and chick embryo 
chorioallantoic membrane (CAM) xenograft models. 
 
A) H&E staining shows that human melanoma tumor from an orthotopic nude mouse 
xenograft model was covered by a thick skin layer consisting of keratin, epidermis 
and dermis, while the tumor from a chick embryo CAM model grew superficially and 
was directly exposed to a topically applied drug.  B) In vivo uptake of FITC-labeled 
decoy peptide (right panel) visualized by microscopy of single cell suspensions 
prepared from tumors.  Control treatment was exposure to DMSO vehicle alone (left 
panel).  Tumors were treated with 25 µM FITC-*Br2 or vehicle control for 4 hours, 
dissected, digested with trypsin, filtered and analyzed by flow cytometry.  C) A 
representative FACS histogram of single cell suspensions of vehicle (filled histogram) 
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2.3.3 TRIP-Br decoy peptides inhibit the growth of CNE2-, Ca Ski- 
and MeWo-derived tumors in the chick embryo CAM model 
 
Separate animal models for human nasopharyngeal cancer, cervical cancer and 
melanoma were developed by generating CNE2-, Ca Ski- or MeWo-derived tumors 
grown on chick embryo CAM to evaluate the anti-tumor effects of the TRIP-Br 
peptides in vivo.  Treatment was initiated on day 12 (2 days after the cancer cell 
inoculation).  Fifty µM of *Br1, Br2 or *Scr decoy peptide in 200 µl of sterile PBS 
was topically applied to established tumors on a daily basis.  PBS (vehicle) was used 
as a negative control.  As shown in Figure 2.5A, the size of the tumor xenografts 
formed by CNE2 cells after *Br1 and *Br2 treatment were significantly smaller than 
those treated with *Scr and PBS.  Similar results were observed with *Br2 treatment 
of Ca Ski and MeWo-derived tumors in the chick embryo CAM model. However, the 
size of *Br1 treated tumors in these two models did not significantly differ, as 
compared to that of *Scr and PBS treated tumors (Figure 2.5 B, C).  When the dosage 
of *Br1 was increased from 50 µM to 100 µM and 200 µM on MeWo cell-derived 
tumors in the CAM human melanoma model, the size of tumors decreased in a dose-
dependent manner (Figure 2.5D).  A significant difference was observed in tumor size 
between the 200 µM *Br1 and *Scr treatment groups, suggesting that the tumor 
growth inhibitory effect of *Br1 is less potent in Ca Ski and MeWo cells grown in 
vivo.  
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                          .   
 
              
Figure 2.5: Histograms showing tumor weight after topical 
administration of decoy peptides on (A) CNE2-, (B) MeWo-, (C) Ca 
Ski- and (D) MeWo- cell-derived tumors in the chick embryo CAM 
model. 
 
 N=36 for (A), N=48 for (B), N=49 for (C) and N=52 for (D).  In (A), (B) and (C), 50 
µM of Br1, Br2 or Scr decoy peptide in 200 µl of sterile PBS was topically 
administered directly onto tumors growing on chick embryo CAM.  PBS served as 
vehicle control.  In (D), tumor xenografts were treated with 50, 100 and 200 µM of 
Br1 or Scr decoy peptide.  Data represents 2-3 independent experiments for each cell 
line.  Asterisk (*) indicates P<0.05 compared with vehicle and *Scr control.  
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2.4     Discussion 
The TRIP-Br family is a recently-classified group of proteins bearing evolutionarily 
conserved functional motifs (cyclin A binding motif, SERTA motif, PHD-
bromodomain binding motif and C-terminal motif) that play important roles in gene 
transcriptional and cell cycle regulation (Calgaro et al., 2002; Watanabe-Fukunaga et 
al., 2005).  TRIP-Br proteins physically interact with the two pivotal G1/S transition 
restriction machineries, cyclin D/CDK4/p16INK4 and E2F1/DP1/pRB, to modulate the 
G1/S transition (Hsu et al., 2001; Sugimoto et al., 1999). These machineries are 
critical in the regulation of cell cycle progression.  Small DNA tumor viruses such as 
SV40, adenovirus and human papillomavirus are capable of transforming normal cells 
to cancerous cells by targeting the E2F1 complex (Adams and Kaelin, 1995; Gupta et 
al., 2003; Trimarchi and Lees, 2002).  In agreement with the physiological role of 
TRIP-Br protein family, multiple members of this family were recently defined as 
oncogenes, including TRIP-Br1, RBT1 (Tang et al., 2005; Darwish et al., 2007) and 
TRIP-Br2 (Cheong et al, unpublished data). Overexpression of these oncogenes have 
been detected in a variety of natural occurring tumor including human squamous cell 
carcinomas of head and neck, ovarian cancer, prostate carcinoma, squamous cell lung 
carcinoma, lung adenocarcinoma, colorectal carcinoma, renal cell carcinoma, 
osteosarcoma and hepatocellular carcinoma. Silencing of TRIP-Br1 gene expression 
by small interfering RNAs (siRNAs) in the ovarian cancer cell line SKOV3 inhibited 
cell growth as well as colony formation on soft agar (Tang et al., 2005). Knocking 
down of RBT1 transcript expression by siRNA substantially reduced the cell growth 
of the human breast adenocarcinoma cell line MCF7 (Darwish et al., 2007) and the 
pancreatic cancer cell line PANC-1 (Curtis et al., 1998; Darwish et al., 2007). These 
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facts provide strong supports for the paradigm of TRIP-Br proteins as a family of pro-
proliferative molecules that promote cell growth. 
 
PHD zinc finger- and/or bromodomain-containing proteins are nuclear proteins that 
play key roles in multiple cellular processes including transcriptional activation and 
chromatin remodeling (Bienz, 2006; Zeng and Zhou, 2002). Various of PHD zinc 
finger- and/or bromodomian-containing proteins including KRIP-1, TIF1α, SP140, 
CBP, p300, PCAF and STAF65γ have been shown to interact with multiple members 
of  the TRIP-Br protein family (TRIP-Br1, TRIP-Br2 and CDCA4)  in vitro and in 
vivo to regulate transcription (Watanabe-Fukunaga et al., 2005; Lai et al., 2007; 
Hirose et al., 2003; Hsu et al., 2001). Mammalian TRIP-Br proteins (TRIP-Br1, 
TRIP-Br2 and RBT1) are able to stimulate the transcription activity of E2F1/DP1 
complex (Darwish et al., 2007; Hsu et al., 2001). Co-expression of PHD zinc finger- 
and bromodomain-containing protein KRIP-1 potentiates the ability of TRIP-Br 
proteins to co-activate E2F1/DP1 (Darwish et al., 2007; Hsu et al., 2001). Thus, 
TRIP-Br proteins are proposed to function to integrate regulatory signals conveyed by 
PHD zinc finger- and/or bromodomain-containing proteins through functional 
interaction with transcription complexes assembled on E2F1-responsive promoters 
(Hsu et al., 2001). The conserved PHD-bromodomain binding motif of TRIP-Br 
proteins has been demonstrated to be the region that is responsible for the physical 
interaction with PHD zinc finger- and bromodomain-containing proteins (Hsu et al., 
2001). Antagonism of the interaction between PHD zinc finger- and/or bromodomain-
containing proteins and TRIP-Br proteins by Penetratin-tagged synthetic decoy 
peptides that mimic the conserved PHD-bromodomain binding motif of TRIP-Br 
proteins in U2OS osteosarcoma cells led to the down-regulation of a subset of 
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endogenous E2F1 responsive genes such as dhfr, cdc2, DNA Polα and fbxw7  in vivo, 
resulting in a global cell cycle arrest characterized by the inhibition of DNA synthesis 
and caspase-3-independent cell death (Sim et al., 2004).  Consistent with our previous 
observations in U2OS cells, TRIP-Br decoy peptides can inhibit the growth of human 
nasopharyngeal cancer cells (NPC2), human cervical cancer cells (Ca Ski) and human 
melanoma cells (MeWo) in vitro. Either TRIP-Br1 or TRIP-Br2 decoy peptides 
inhibited cancer cell proliferation, implying that TRIP-Br1 and TRIP-Br2 may not be 
functionally redundant in cell cycle regulation.  The TRIP-Br2 decoy peptide has been 
consistently observed to be a more potent inhibitor of cellular proliferation than the 
TRIP-Br1 decoy peptide.  This finding corroborates well with our previous 
observation that *Br2 is a more potent antagonist than *Br1 in both protein-protein 
interaction studies, functional assays and in vitro proliferation assays (Sim et al., 
2006; Sim et al., 2004).  
 
In the chick embryo CAM xenograft model, topically applied TRIP-Br decoy peptides 
can significantly inhibit the growth of tumors derived from cancer cell lines. This 
suggests that antagonism of the TRIP-Br integrator function is effective in inhibiting 
tumor cell growth in vivo.  The chick embryo CAM model has been recently 
established as a great animal model for tumor angiogenesis studies (Dani and 
Espindola, 2002; Kisker et al., 2001; Ribatti et al., 2000).  We chose this model for 
our in vivo decoy peptide proof-of-principle study based on several reasons.  Firstly, 
the tumors produced by the chick embryo CAM model are more physiological in 
terms of mimicking the superficial origin and the papillary out-growth pattern of early 
stages of nasopharyngeal, cervical and skin cancer (Yokoyama et al., 1969). For 
instance, 90% of cervical cancers arise from squamous cells lining the cervical os.  
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These lesions usually progress through mild, moderate and severe stages of dysplasia 
(cancer in situ) before progressing to invasive tumors.  The nude mouse subcutaneous 
xenograft model in which cervical cancer cells grow under a full skin layer and 
subcutaneous tissue, does not reflect the biological behavior of cervical cancer. In 
contrast, the highly vascularized and moist chick embryo CAM resembles human 
cervical or nasopharyngeal mucosa.  Secondly, the chick embryo CAM xenograft 
model is better than the nude mouse subcutaneous xenograft model for evaluating the 
efficacy of topically applied compounds in the treatment of superficial lesion since the 
drug delivery to tumor cells, without the skin barrier, is expected to be more superior.  
Furthermore, the chick embryo CAM model bypasses the necessity of preparing 
ointment/plaster for drug delivery in the nude mouse model.  It also avoids the 
troublesome issue of “self-grooming” behavior in the mouse.  
 
Taken together, the observed anti-proliferative effect of TRIP-Br decoy peptides on 
cancer cells in vitro and in vivo suggests that TRIP-Br proteins, which function as 
regulators of the “master switch” for G1/S transition, may represent important 
chemotherapeutic drug targets for superficial cutaneous and intracavitary 
hyperproliferative lesions.  TRIP-Br decoy peptides may be effective as a primary or 
adjuvant therapy to treat cervical dysplasia, genital warts or early stages of non-
invasive oral and skin cancer in the form of ointment, plaster or suppository. To 
translate this result into clinical application, much more works remains to be done.  
These include at least developing a suppository or ointment for the topical application 
of TRIP-Br decoy peptide in collaboration with the pharmacist, establishing a mouse 
model with superficial cutaneous or intracavitary hyperproliferative lesions, further 
evaluating the therapeutic potential of the suppository or ointment mediated TRIP-Br 
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decoy peptide in this mouse model, etc. These works are essential to move the current 
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CHAPER FOUR 
REGULATION OF TRIP-BR1 BY
 
SERINE/THREONINE PROTEIN PHOSPHATASE 2A
 
 
3.1     Introduction 
 
3.1.1   Protein kinases and protein phosphatases 
 
Protein phosphorylation and dephosphorylation regulate virtually every signal 
transduction pathway in the eukaryotic cell. It is the primary means of switching the 
activity of a cellular protein rapidly from one state to another. Estimates of 
phosphorylation in the eukaryotic cell range from 30% of all proteins to the “majority 
of human proteins may be phosphorylated at multiple sites (totally 100 000 sites)” 
(Hubbard and Cohen, 1993; Zhang et al., 2002). The phosphorylation state of a 
protein is a dynamic process controlled by both protein kinases and protein 
phosphatases. Biochemically, protein kinases function to transfer a phosphate moiety 
from adenosine triphosphate (ATP) to the hydroxyl groups on serine, threonine and 
more rarely tyrosine, while phosphatases removes a phosphate group from these 
residues by hydrolyzing phosphoric acid monoesters into a phosphate and a molecule 
with a free hydroxyl group. A well-balanced network of kinases and phosphatases is 
crucial for cells to react appropriately and in a normal physiologic manner to 
environmental stimuli, to divide in a regulated manner or to maintain a terminally 
differentiated state.  
 
The human genome contains approximately 510 protein kinases (Manning et al., 
2002). In contrast, only about 100 protein phosphatases have been identified (Venter 
et al., 2001).  Phosphatases can be divided based upon their substrate specificity, such 
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as tyrosine specific phosphatases, serine/threonine specific phosphatases, dual 
specificity phosphatases, histidine phosphatases, etc. Serine/threonine specific 
phosphatases constitute one of the most important classes of phosphatases given the 
number of phosphorylated serine and theroine residues that exist in eukaryotic cells 
compared to other residues. Serine/ threonine specific phosphatases are further 
subdivided into protein phosphatase 1 (PP1), protein phosphatase 2 (PP2), protein 
phosphatase 4 (PP4) and protein phosphatase 5 (PP5) based on biochemical 
parameters. Among the protein phosphatase 2 (PP2) class, there are spontaneously 
active (PP2A), Ca2+-dependent (PP2B) and Mg2+-dependent (PP2C) sub-classes 
(Wera and Hemmings, 1995). 
 
 
3.1.2   Protein phosphatase 2A (PP2A) 
 
3.1.2.1  Subunit composition, localization and distribution 
Protein phosphatase 2A (PP2A) comprises a diverse family of phosphoserine- and 
phosphothreonine-specific phosphatases implicated in many cellular processes 
including the regulation of metabolism, transcription, RNA splicing, translation, 
differentiation, cell cycle, oncogenic transformation and signal transduction in all 
eukaryotic cells. This enzyme family is tightly regulated, have restricted substrate 
specificity, and display tissue- and cell-specific distribution (Sontag, 2001).  
 
PP2A is a multimeric enzyme. As shown in Figure 3.1, the PP2A holoenzyme 
consists of a heterodimeric core enzyme comprised of a 65 kD scaffolding subunit (A 
subunit), a 36 kD catalytic subunit (C subunit) and a variable regulatory subunit (B 
subunit) (Turowski et al., 1997). Although heterodimeric core enzymes may exist in 
tissue, the prevalent PP2A enzymes are ABC heterotrimers in vivo (Virshup, 2000). 
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PP2A catalytic subunits are highly expressed in various cell types and tissues. It 
comprises 0.3–1% of cellular protein (Lin et al., 1998; Ruediger et al., 1991). 
Molecular cloning reveals that the PP2A-C gene is remarkably conserved from lower 
organisms to mammal (Cohen et al., 1990). Two mammalian PP2AC isoforms are 
present, α and β, which share 97% identity in their primary sequence with 7 of 8 
different residues located within the first 30 amino acids (Gotz et al., 1998). They are 
encoded by different genes, localized to human chromosome 5q23-31 for α and to 
8p12-11.2 for β (Arino et al., 1988; Jones et al., 1993).  Analysis of the expression of 
the two isoforms shows that Cα transcripts are about 10-fold more abundant than Cβ 
due to the stronger Cα promoter (Khew-Goodall and Hemmings, 1988). Despite a 
97% amino acid identity, Cβ cannot completely compensate for the absence of Cα at 
the organism level, suggested by embryonic lethality in PP2A-Cα homozygous null 
mutant mice (Gotz et al., 1998) 
 
 
The structure of PP2A scaffolding subunit (A) is unique, entirely composed of 15 
tandem HEAT-like (Huntingtin-Elongation-A subunit-TOR-like) repeats of 39 amino 
acid residues. Crystal structure determination has revealed that PP2A-A subunit is a 
hook-shaped protein, a configuration that can be simulated using the thumb and 
forefinger to form a hook (Groves et al., 1999). The evolutionarily conserved PR65 
residues and the exposed hydrophobic surfaces are localized to the intra-repeat turns, 
connecting the two helices of each HEAT motif, and are likely to constitute the sites 
of interaction with the catalytic and the regulatory subunits. Different B subunits 
interact via the same or overlapping sites within the A subunit of the core dimer, 
which explains why the association of multiple B subunits is mutually exclusive 
(Ruediger et al., 1994; Ruediger et al., 1992). Similar to the catalytic subunit, there 
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are two mammalian gene isoforms for the A subunit, Aα and Aβ, which share 86% 
sequence identity. PP2A-Aβ appears to be much less abundant than PP2A-Aα, 
although both appear to be ubiquitously expressed (Hemmings et al., 1990). 
 
The PP2A regulatory subunit is the key subunit that allows PP2A to act in a diverse 
set of functions.  To date, a number of proteins that function as PP2A-B subunits have 
been identified. They are classified as members of the B, B', B'' and B''' families based 
on sequence similarity. These B subunits competitively bind to a shared binding site 
on the A subunit. While the A and C subunits are present in all cells, some of the B 
subunits are differentially expressed in a tissue-specific manner or only during certain 
developmental stages (Sontag, 2001). Numerous PP2A-B subunits associate with the 
PP2A core enzyme to form a large repertoire of heteromultimeric holoenzymes, 
although only two C subunit isoforms of PP2A exist (Janssens and Goris, 2001). 
Members of different B subunit families share almost no sequence similarity even 
though they are all capable of binding to similar segments of the PP2A-A scaffolding 
subunit. The main isoforms, tissue distribution and cellular localization of each PP2A-
B family are listed in Table 3.1. It has become increasingly clear that a major function 
of these regulatory subunits is to target the PP2A holoenzyme to distinct intracellular 
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Figure 3.1: Structure of PP2A holoenzyme. 
 
The common heterotrimeric form of PP2A containing the catalytic subunit (C), the 
structural A/PR65 subunit (A) and a regulatory/targeting B subunit is shown. In 
mammals, A and C are encoded by two genes (α and β) ; the B/PR55 subunits are 
encoded by four related genes (α, β, γ, δ) ; the B'/PR61 family are encoded by five 
related genes (α, β, γ, δ, ε), some of which give rise to alternatively spliced products; 
the B'' family probably contains three related genes, encoding PR48, PR59 and the 
splice variants PR72 and PR130; SG2NA and striatin comprise the B''' subunit family. 
(Figure modified from : Janssens and Goris, 2001) 
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                     Table 3.1: Nomenclature and distribution of regulatory B-type subunits. Table 
                     source: Sontag, 2001 (Permission to cite copyright work has been granted) 
 
Regulatory 
Subunits  Isoforms  Cell/Tissue Distribution  Known Subcellular Distribution 
B(B55) 
family 
Bα or B55 or 
PR55  
Widespread, predominant PP2A 
regulatory subunit (Mayer et al., 
1991) 
Microtubules (Hiraga and Tamura, 
2000), neurofilaments(Saito et al., 
1995), vimentin (Turowski et al., 
1999),cytoplasm (Strack et al., 
1998),membrane (Sim et al., 2006), 
nucleus(Sontag et al., 1999), 
Golgi/reticulum (Sontag et al., 1995) 
 Bβ Enriched in brain and testis 
(Hatano et al., 1993) 
Cytosol (Strack et al., 1998) 
 Bγ Brain-specific (Akiyama et al., 
1995; Zolnierowicz et al., 1994) 
Enriched in cytoskeletal fraction 
(Strack et al., 1998) 
  Bδ Widely expressed, enriched in 
testis  
 Cytosol (Strack et al., 1999)  
B'(B56) 
family  
B56α Highly expressed in heart and 
skeletal muscle  
Cytoplasm (McCright et al., 1996) 
 B56β or B'α  Highly expressed in brain 
(Csortos et al., 1996; McCright et 
al., 1996) 
 Cytoplasm (McCright et al., 1996) 
 B56γ1 or 
B'β1-4 or 
B'α3 
Highly expressed in heart and 
skeletal muscle (Csortos et al., 
1996; McCright et al., 1996; 
Tehrani et al., 1996) 
Cytoplasm>nucleus(Ito et al., 2000; 
McCright et al., 1996; Tehrani et al., 
1996), focal adhesion (McCright et 
al., 1996) 
 B56γ2 or 
B'α2 
Highly expressed in heart and 
skeletal muscle  
(Csortos et al., 1996; McCright et 
al., 1996; Tehrani et al., 1996) 
Nucleus>cytoplasm (Ito et al., 2000; 
McCright et al., 1996; Tehrani et al., 
1996) 
 B56δ or B'γ 
or  
74-kDa/B'δ 
Highly expressed in brain 
(McCright et al., 1996; Tanabe et 
al., 1996)  
Nucleus, cytosol, mitochondria, 
microsome (Nagase et al., 1997)  
 B56ε or B'δ Highly expressed in brain 
(McCright et al., 1996) 
Cytoplasm (McCright et al., 1996)  
 B56ζ1 or 
B56γ3 or 
B'α1a 
Highly expressed in heart and 
skeletal muscle (McCright et al., 
1996) 
Nucleus>>>cytoplasm (Ito et al., 
2000; McCright et al., 1996; Tehrani 
et al., 1996) 
  B56ζ2 or 
B56γ2 or 
B'α2a 
Highly expressed in heart and 
skeletal muscle (McCright et al., 
1996; Tehrani et al., 1996) 
Nucleus>cytoplasm (Ito et al., 2000; 
McCright et al., 1996; Tehrani et al., 
1996) 
B'' family PR72 or 
Bδ/72 kDa 
Enriched in heart and skeletal 
muscle (Hendrix et al., 1993) 
Cytosol (Hendrix et al., 1993)  
 PR130 Heart, brain, lung, muscle, 
kidney (Hendrix et al., 1993)   
Centrosome and Golgi (Takahashi et 
al., 1999)  
 PR59  Heart, kidney, lung, but not 
skeletal muscle (Voorhoeve et 
al., 1999)  
Nucleus (Voorhoeve et al., 1999)  
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3.1.2.2    Biological role of PP2A 
3.1.2.2.1 Regulation by PP2A via protein-protein interaction 
PP2A has a role in many cellular processes, and its specific function is likely to be 
tightly controlled by its associated proteins. For example, PP2A serves as an integral 
component of multi-molecular signaling complexes through its binding to specific 
kinases such as casein kinase 2 (CK2) (Lebrin et al., 1999), CaM kinase IV (CaMkIV) 
(Westphal et al., 1998), PAK, and p70 S6 kinase (Westphal et al., 1999). In the case 
of CaM kinase IV, the association with PP2A-Bα holoenzyme serves to both suppress 
basal CaMkIV activity and to rapidly decrease CaMkIV activity following calcium 
signaling in brain and lymphocytes (Westphal et al., 1998). PP2A-B holoenzymes 
regulate Wnt signaling through their association with a multi-protein complex 
containing axin, adenosis polyposis coli (APC), β-catenin and GSK-3β. In this case, 
the C subunit directly interacts with the scaffolding protein axin, whereas the B' 
subunit binds to APC (Seeling et al., 1999). 
 
PP2A also interacts with proteins that target the phosphatase to perform specific 
cellular regulatory functions. A PP2A complex comprised of the regulatory subunit 
PR48 plays an important role in the initiation of DNA replication through interaction 
with Cdc6, an essential component of pre-replication complexes (Yan et al., 2000). 
The phosphatase activity of a PP2A holoenzyme comprised of a specific B' regulatory 
subunit has been implicated in the regulation of cell death through a mechanism 
involving its association with and dephosphorylation of Bcl-2, an anti-apoptotic factor 
that is normally activated by phosphorylation in response to survival signals (Lin et al., 
2006; Ruvolo et al., 2002). The PR59 subunit binds to p107, a member of the pRB 
family of pocket proteins that functions through binding to E2F1/DP1 heterodimers,  
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to regulate cell cycle progression at the G1/S checkpoint (Voorhoeve et al., 1999). 
Interaction of a B' subunit with Pim-1 protein kinases links PP2A to cytokine 
signaling (Losman et al., 2003; Ma et al., 2007). The cyclin G-AB'αC complex 
modulates p53-dependent signaling pathways (Okamoto et al., 1996). Association of 
the HOX11 cellular oncogene with the C catalytic subunit leads to disruption of a 
G2/M cell cycle checkpoint (Kawabe et al., 1997). Interaction of the C catalytic 
subunit with the alpha 4 protein (α4) links PP2A to Tor signaling, a rapamycin-
sensitive pathway that stimulates protein synthesis in response to mitogens (Chung et 
al., 1999).  
 
Through its interaction with certain substrates, PP2A can also be directed to specific 
subcellular locations where it exerts its functions. For instance, interaction with 
paxillin, vimentin, tubulin, and CG-NAP directs selective PP2A holoenzymes to 
discrete cellular domains, i.e. focal adhesions (Ito et al., 2000), intermediate filaments 
(Turowski et al., 1999), microtubules (Hiraga and Tamura, 2000; Sontag et al., 1995; 
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3.1.2.2.2 PP2A and cell cycle 
 
PP2A has been shown to be involved in the regulation of the G1 and G2/M phases of 
the cell cycle. PP2A appears to have stimulatory effects during the early phases of the 
cell cycle by affecting the activity of G1-specifc CDK complexes. In particular, the 
inhibition of PP2A activity results in: 1) an inhibition of CDK4, CDK6, and CDK2 
protein kinase activity; 2) an induction of cyclin-dependent kinase inhibitors p21 and 
p27; and 3) a decrease in complex formation of key regulatory subunits of G1 CDK 
complexes with cyclin D2 and cyclin E.  The net result is a decrease in pRB 
phosphorylation and maintenance of E2F1/DP1 heterodimers in a transcriptionally 
inactive state. As a consequence, cells become arrested in the G1 phase of the cell 
cycle (Yan and Mumby, 1999). Among the multiple mechanisms that suppress CDK 
activity, inhibition of cyclin D-CDK4 complex formation appears to be a major cause 
for reduced pRB phosphorylation. In other words, PP2A activity is crucial for the 
activation or maintenance of CDK activity in G1. In another report, inhibition PP2A in 
NIH3T3 cells by okadaic acid causes a G1 arrest that correlates with decreased pRB 
phosphorylation, decreased CDK activity, and a block in cyclin A, CDC2, and CDK2 
expression (Schonthal and Feramisco, 1993).  In addition, overexpression of the PP2A 
catalytic subunit positively regulates CDC2 gene expression (Jaramillo-Babb et al., 
1996).  These data indicate that PP2A activity is required for the normal regulation of 
G1 CDKs and that it plays a positive role in progression through the early phases of 
the cell cycle that lead to S phase entry and DNA replication. 
 
A role for PP2A in regulation of the G2/M transition was first demonstrated by Goris 
et al, who elegantly showed that injection of the phosphatase inhibitor okadaic acid 
into Xenopus oocytes induces the formation of active M-phase-promoting factor 
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(MPF), resulting in meiotic maturation (Goris et al., 1989). This suggested that an 
OA-sensitive phosphatase negatively regulates entry into mitosis. This OA-sensitive 
phosphatase was later identified as PP2A. PP2A is required to keep MPF (or cyclin B-
CDC2 or cyclin B-CDK1) in its inactive precursor form by inhibiting the activities of 
both CAK (Cdk-activating kinase) and Wee1, which function to phosphorylate CDC2 
at Thr161 and Tyr15 to facilitate its activation (Kinoshita et al., 1993; Lee et al., 
1994). Cyclin B-CDC2 activity is required for entry and progression through the 
G2/M transition of the cell cycle. PP2A also inhibits complete Cdc25 phosphorylation 
(and activation) by counteracting the polo-like kinase (Plx1) (Clarke et al., 1993). 
Notably, in contrast to its role in regulating entry into mitosis, PP2A activity also 
plays a positive role in exit from mitosis by facilitating cyclin B degradation and by 
dephosphorylating specific mitotic substrates of activated cyclin B-CDC2. 
 
The molecular basis for the seemingly opposed roles of PP2A in G1 and the G2/M 
transition remains unclear. This apparent paradox may be explained by the activity of 
distinct PP2A holoenzymes that are targeted at different G1 and G2/M phase substrates 
(Schonthal, 2001). 
 
3.1.2.2.3 PP2A and tumorigenesis 
 
PP2A was initially considered as a tumor suppressor. The first evidence for a negative 
role for PP2A in carcinogenesis arose from the observation that the tumor promoter 
okadaic acid is a potent inhibitor of PP2A activity (Bialojan and Takai, 1988). 
Treatment of cells with okadaic acid results in the increased expression of several 
proto-oncogenes (Bialojan and Takai, 1988). In agreement with the proposed role of 
PP2A as a “negative regulator” of cellular growth, overexpression of PP2A-A leads to 
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multinucleated cells (Wera et al., 1995).  The oncogenic viral protein polyoma small 
T antigen is able to transform mammalian cells by binding to the PP2A core enzyme 
and displacing the B' regulatory subunit. As a result, the phosphorylation of specific 
PP2A-B' substrates is enhanced, leading to increased cell proliferation, anchorage-
independent growth and eventually tumor formation (Chen et al., 2004; Pallas et al., 
1990; Walter et al., 1990). Infrequent mutations of both α and β isoforms of PP2A-A 
have been found in a variety of human cancer including breast cancer, colorectal 
carcinoma and lung cancer (Calin et al., 2000; Takagi et al., 2000). These data 
indicate a potential role for PP2A as a tumor suppressor.  
 
On the other hand, it has been shown that PP2A is able to exert positive effects on cell 
growth and proliferation, a property consistent with a role as an oncogene. Mice 
lacking the α isoform of PP2A catalytic subunit die in utero because mesoderm is not 
formed in these mice (Gotz et al., 1998). This indicates that PP2A is essential for 
proper embryonic development and that complete absence of PP2A activity is 
detrimental to cell growth and survival. In addition, it has also been demonstrated that 
PP2A is directly and positively engaged in the initiation of chromosomal DNA 
replication, as evidenced by the suppressed firing of replication origins when PP2A 
holoenzyme was immunodepleted in a Xenopus cell-free replication system (Lin et al., 
1998). Further investigation revealed that Cdc6, a protein that is required for the 
formation of the pre-replication complex and whose activity is rate-limiting for the 
initiation of DNA replication, is activated by PP2A-mediated dephosphorylation (Yan 
et al., 2000). Moreover, PP2A functions to positively regulate the activity of proto-
oncogenes. For example, PP2A positively regulates securin, a protein that is 
absolutely required for sister chromatid separation and is highly expressed in many 
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tumor types (Gil-Bernabe et al., 2006). Raf-1, a proto-oncoprotein that functions as a 
MAP kinase kinase kinase is associated with PP2A. PP2A facilitates raf-1 kinase 
activity by maintaining serine 259 in a dephosphorylated state (Dominguez et al., 
1998; Heaney et al., 2000). Long-term treatment of cells in culture with okadaic acid 
at concentrations that completely inhibit PP2A results in severe cytotoxicity 
(Schonthal, 1992). PP2A-Cβ has been reported to be overexpressed in chemically 
induced rat liver tumors (Kitagawa et al., 1988b). Increased levels of the PP2A-Cα 
subunit were found in several transformed cell lines (Kitagawa et al., 1988a). 
Furthermore, solid tumors or cell lines transfected with the oncogenes ret-II, Ki-ras, 
or c-raf have elevated PP2A catalytic subunit transcript levels (Nagao et al., 1989).  
 
Taken together, these data support the notion that PP2A plays both positive as well as 
negative roles in cell proliferation. This is not unexpected considering that PP2A is a 
multimeric enzyme system that interacts with diverse protein partners. Up to 75 
different holoenzyme combinations may exist. This number is believed to be 
underestimated as new PP2A B regulatory subunit is still emerging. Thus, the roles of 
PP2A in human tumorigenesis are likely to be substrate-dependent and signaling 
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3.2      Materials and Methods 
 
3.2.1    Materials 
3.2.1.1   Plasmid DNA  
The use of pGEX-mTRIP-Br1 expression plasmid has been previously described (Hsu 
et al, 2001). The pD30-PP2A-FLAG-A and pD30-PP2A-HA-C were kindly provided 
by Dr. Rosalie C. Sears (Oregon Health & Sciences University, Portland, Oregon). 
The pCEPL-PP2A-Bα was a generous gift from Dr. David Virshup (Huntsman 
Cancer Institute, University of Utah). The pGL3-6×E2F1-TATA/Luciferase reporter 
plasmid, pCMV-E2F1, pCMV-DP1 and pcDNA-HA-TRIP-Br1 were previously 
described (Gupta et al, 2003). Thymidine kinase promoter-driven Renilla luciferase 
construct pTK-RL was obtained from Dr. Jeremy S. Duffield (Brigham and Women’s 
Hospital, Harvard Medical School). Adenovirus TRIP-Br1 expression construct 
pAdenoX-FLAG-SEI-1/EGFP was kindly provided by Dr. Eiji Hara (University of 
Tokushima).  
 
3.2.1.2 Biochemical reagents   
The generation and characterization of mouse monoclonal antibody against TRIP-Br1 
is described in Section 2.2.2.1. Mouse monoclonal antibody for GST (B-14), HA 
(Y11) and β-Tubulin (D-10), rabbit polyclonal antibody for c-Myc (N-262),  goat 
polyclonal antibody for  PP2A-A (c-20), and Lamin B (c-20) were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Rabbit monoclonal antibody for PP2A-Bα subunit 
(100C1) was from Cell Signaling Technology (Beverly, MA). Mouse monoclonal 
antibody for PP2A catalytic subunit was from BD Biosciences (San Jose, CA). Mouse 
monoclonal antibody to securin (DCS-280) was from Abcam (Cambridge, MA). 
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Mouse monoclonal antibody to GAPDH (6C5) was from Ambion (Austin, TX). 
ANTI-FLAG mouse monoclonal (M2) was from Sigma (St. Louis, MO).  Anti-
phosphoserine monoclonal antibody (Q5) was from Qiagen (Valencia, CA). HRP-
conjugated anti-mouse, anti-rabbit and anti-goat secondary antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Small interfering RNA (siRNA) 
SMARTpools for PP2A-Cα (PPP2CA) and control siRNA were purchased from 
Dharmacon (Lafayette, CO). Okadaic acid was from LC Laboratories (Woburn, MA). 
 
3.2.2    Methods 
3.2.2.1   Cell culture and maintenance 
Human kidney epithelium cell lines including 786-O (human kidney clear cell 
carcinoma), 769-P (human kidney clear cell carcinoma), HEK 293 (human embryonic 
kidney epithelial) and HK2 (human adult kidney epithelial ) cells were maintained at 
37oC in a humidified atmosphere of 5% carbon dioxide (CO2) and grown in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) supplemented with 10% 
characterized fetal bovine serum (FBS) (Hyclone®) and anti-microbial agents (50 
µg/ml gentamycin).  Cells were passage at 2 to 3-day intervals.  During each passage, 
spent growth medium was aspirated and cells were washed once with sterile 1×PBS.  
Thereafter, cells were treated with 1 ml of trypsin (Sigma) for 2 minutes at 37oC. The 
trypsin treatment was quenched by adding serum-containing growth medium and 1:4 
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3.2.2.2  Expression and purification of GST fusion proteins   
GST-mTRIP-Br1 fusion protein and GST control proteins were induced and purified 
as described in Current Protocol in Molecular Biology. Briefly, 0.2 mM Isopropyl β-
D-1-thiogalactopyranoside (IPTG) was used to induce the expression of GST-fusion 
protein from Escherichia. coli (E. coli) at 28-30ºC for 12 hours. The bacteria was 
lysed by a freeze (dry ice)-thaw (20ºC) approach. The bacterial lysate was mixed with 
1% Triton X -100 (final concentration) and purified using glutathione agarose beads 
(Sigma). The beads were then washed six times, aliquoted and stored frozen at -80 ºC 
until use. The purified protein was validated by SDS-PAGE, followed by Coomassie 
blue staining and immunodetection of GST-TRIP-Br1 and GST protein.  
 
3.2.2.3  GST pull-down assay 
One P10 of subconfluent HEK 293 or 769-P cells were lysed in 1ml of RIPA lysis 
buffer with protease and phosphatase inhibitor [150 mM NaCl, 50 mM Tris-HCl (pH 
7.5), 1% Nonidet P-40 (NP40), 1 mM sodium vanadate, 5 mM sodium fluoride, 1 mM 
phenylmethylsulfonylfluoride (PMSF), 1mg/ml aprotinin, 1 mg/ml pepstatin and 1 
mg/ml leupeptin] at 4°C for 30 min. Cellular proteins were pre-cleared with 
glutathione agarose beads (Sigma) for 2 h. After centrifugation, the cellular extract 
was incubated with appropriate amount of GST or GST-TRIP-Br1 protein that 
immobilized on gluthatione-agarose beads and incubated for 2 hours at 4°C with 
tumbling.  The beads were washed six times in RIPA lysis buffer and the bound 
proteins were eluted by heating the samples at 95°C for 5 minutes in 1×SDS sample 
buffer. Thereafter, the eluted proteins were subjected to SDS-PAGE followed by 
visualization (Coomassie blue or silver staining) or immunodetection of protein of 
interest.  
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3.2.2.4  Silver staining  
Proteins on SDS-PAGE gel were stained with silver nitrate as summarized bellow. For 
each step, 50 ml of reagent was used per mini-gel.  
 
Step                      Reagent Duration 
Fixation 50% methanol and 5% acetic acid 
in deionized water 
1 hour to overnight 
Wash 50% methanol 3 x 10 minutes 
Wash Deionized water  2x 10 minutes 
Pretreating 0.02% sodium thiosulfate in 
deionized water 
1 minute exactly 
Rinsing Deionized water 3 x 20 seconds exactly 
Staining 0.2% silver nitrate and  0.075% 
formaldehyde (37%) in deionized 
water 
20 minutes at 4 °C 
Wash Deionized water 3 x 20 seconds 
Development 6% sodium carbonate, 0.05%  
formaldehyde (37%) and 0.0004% 
sodium thiosulfate in deionized 
water 
10 minutes or more depending 
on the intensity and 
background 
Wash Deionized water 2 x 2 minutes 
Stopping  50% methanol and 5% acetic acid 
in deionized water 
5 minutes 
Wash 50% methanol 3 x 10 minutes at 4 °C 
Storage 1 %  acetic acid in deionized  




3.2.2.5  Coomassie blue staining 
 
Gel was fixed in 10 volumes of 1× fixer (50% methanol and 10% acetic acid) for 30 
minutes at room temperature and then stained in 10 volumes of Coommassie blue 
stain (500 ml methanol+ 1.0 g Brilliant Blue R-250 + 400 ml milli-Q water + 100 ml 
acetic acid) for 1 hour at room temperature. Thereafter, gel were destained using 
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destain solution (45% methanol and 10% acetic acid) with shaking until the 
signal/background ratio is satisfactory. The gel was then stored in 5% acetic acid 
solution at 4°C for further analysis. 
 
3.2.2.6  Liquid chromatography/mass spectrometry  
The protein bands on the silver stained SDS-PAGE gel were excised with caution to 
avoid contamination and sent to Taplin Biological Mass Spectrometry Facility 
(Harvard Medical School) for further analysis, which includes in-gel digestion of gel 
bands, micro-capillary LC/MS/MS analysis, protein database searching and data 
analysis. 
 
3.2.2.7  Immunoprecipitation assay (IP) 
Subconfluent HK2 or 786-O cells were lysed at 4°C in RIPA lysis buffer with 
protease and phosphatase inhibitors for 30 min (refer to Section 3.2.2.3). Cellular 
proteins were pre-cleared with Protein A/G agarose beads (Santa Cruz Biotechnology) 
for 2 h. After centrifugation at 16,000 g for 10 minutes at 4°C, the cellular extract was 
incubated with anti-TRIP-Br1 monoclonal antibody (TB1-27#2) or mouse IgG control 
and protein A/G beads overnight at 4°C with tumbling.  The beads were washed six 
times in RIPA lysis buffer, and the bound proteins were eluted by heating the samples 
at 95°C for 5 min in 1×SDS sample buffer. Thereafter, the eluted proteins were 
subjected to SDS-PAGE followed by immunodetection of PP2A-Bα, PP2A-C, PP2A-
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3.2.2.8 Serine/threonine protein phosphatase activity assays 
 
 
The proteins pulled-down by GST or GST-TRIP-Br1 fusion protein from 769-P or 
HEK-293 cellular lysate were assessed to see whether they possess any 
serine/threonine protein phosphatase activity. The activity of serine/threonine 
phosphatase was determined by a nonradioactive approach using molybdate dye-
based phosphatase assay kit (Promega) according to the manufacturer’s 
recommendations. We first obtained the proteins pulled-down by GST or GST-TRIP-
Br1, as previously described, from lysates prepared in RIPA lysis buffer without 
phosphatase inhibitors (NaF and Na3VO4) and washed in PP2A buffer (50 mM 
imidazole, pH 7.2, 0.2 mM EGTA, 0.02% β-mercaptoethanol, and 0.1 mg/ml bovine 
serum albumin). Serine/threonine phosphatase activity in GST or GST-TRIP-Br1 or 
GST pull-down was determined by measuring the ability of such immune complexes 
to dephosphorylate a synthetic phosphothreonine peptide, RA[pT]VA, which is a 
known substrate of PP2A. The assay was conducted in the present of Protein A/G 
agarose beads. The reaction was stopped by the addition of 300 µl molybdate dye-
additive mixture, and color was developed by incubating the mixture for 30 minutes at 
room temperature. A standard curve was obtained using inorganic phosphate at 
concentrations ranging from 500 to 2,000 µM. Absorbance at 600 nm was measured, 
and the amount of phosphate released was then calculated using the standard curve. 
Specific GST-TRIP-Br1 pull-down phosphatase activity was calculated relative to the 
phosphatase activity obtained from GST pull-down only, which was set arbitrarily at 
1.0. To assess whether the phosphatase activity associated with GST-TRIP-Br1 pull-
down was sensitive to the PP2A inhibitor, 10 nM of okadiac acid or DMSO vehicle 
control were added to the phosphatase reaction. 
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3.2.2.9  Indirect immunofluorescence staining of cells 
Untransfected 786-O cells or 769-P cells infected with adenovirus encoding TRIP-Br1 
or COS-7 cells transfected with pcDNA-HA-TRIP-Br1 expression construct was 
grown to 30-50 % confluence on sterile coverslips in a 35 mm plate at 37 °C in a 
humidified atmosphere of 5% carbon dioxide (CO2) for 24 hours. Cells were washed 
three times with PBS, fixed by 4% paraformaldehyde (pH 7.4) for 20 minutes, and 
permeabilized by 0.2% Triton-X 100 for 10 minutes.   Cells were then incubated in 
blocking reagent (1% of goat serum in PBS) for 1 hour, followed  by immunostaining 
with anti-TRIP-Br1 (1:10), anti-FLAG (1:100) or anti-HA (1:50) antibody that was 
diluted in 1% of goat serum/PBS at room temperature for 1 hour. Thereafter, the cells 
were washed for three times in PBS (5 minutes each wash) and incubated with FITC- 
or Cy3-labeled   goat anti-mouse antibody (1:200) for 1 hour. After five wash, the 
cells were mounted with DAPI/VectorShield® (Vector Laboratories) and viewed 
under an immunofluorescence microscope with the appropriate filters.  All procedures 
were carried out at room temperature.   
 
 
 3.2.2.10 Subcellular fractionation 
 
Fractionation was performed using NE-PER nuclear and cytoplasmic extraction 
reagents according to the manufacturer's instructions (Pierce, Rockford, IL). The 
nuclear fraction pellet was further washed with cytoplasmic buffer for two times upon 
the removal of the cytoplasmic fraction so as to minimize cross-contamination of the 
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3.2.2.11 Co-localization study of TRIP-Br1 and PP2A-Bα 
HK-2 and 786-O cells were prepared as described in Section 3.2.2.9 prior to primary 
immunostaining with anti-TRIP-Br1 mouse monoclonal (1:10) and anti-PP2A-Bα 
rabbit monoclonal antibody (100c) (1:100) as primary antibody. Goat anti-mouse 
antibody conjugated with FITC (1:200) and goat anti-rabbit conjugated with Cy3 
(1:400) were added as the secondary antibody. Cells were blocked with a blocking 
reagent (1% of goat serum in PBS) before primary antibody incubation to minimize 
the non-specific binding. Mouse and rabbit IgG were used as negative controls for the 
primary immunostaining of cells. 
 
3.2.2.12  DNA and siRNA transfection procedures  
 
DNA and siRNA transfections were performed using Lipofectamine 2000 (Invitrogen, 
CA) according to manufacturer’s instructions. For DNA transfection, cells were 
grown to approximately 90-95% confluence before transfection. For SMARTpool 
siRNA transfections, cells were grown to approximately 60-70% confluence 
according the manufacturer’s instructions. The total DNA transfected was kept 
constant by the addition of empty control plasmid. The transfected cells were 
maintained in DMEM supplemented with 10% FBS until their harvest for further 
manipulations. 
 
3.2.2.13 Preparation of proteins from tissue culture 
To prepare protein samples for Western blot analysis, cells grown in tissue culture 
vessel were washed at least two times with ice-cold PBS and lysed in situ in 4% SDS 
at room temperature. DNA in the cell lysate was sheared by passing through a 28G 
needle. Whole cell lysates were heated at 100oC for 5 minutes immediately after lysis 
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and kept frozen at -20oC for further analysis. To prepare cell lysate for 
immunoprecipetation or GST-pull down, cells were lysed in RIPA lysis buffer with 
protease/phosphatase inhibitors (refer to Section 3.2.2.3) at 4oC for 15 minutes.  
 
3.2.2.14 Protein quantitation 
All the protein samples were quantitated prior to Western blot analysis by BCA 
Protein Assay Reagent (Pierce) to ensure that equal amounts of proteins were loaded. 
Whole cell lysates were heated at 100oC for 5 minutes prior to protein quantitation 
 
3.2.2.15  Western blot for protein immunodetection 
Whole cell lysate in 4% of SDS lysis buffer was resolved on 10-12% SDS-PAGE, 
using  1× running buffer (25 mM Tris pH 8.6, 0.19 M glycine, 0.1% SDS), in a mini 
vertical electrophoresis apparatus (Bio-Rad Laboratories, Philadelphia, PA) at 
constant voltage (100 V). Stacking gel was prepared in upper Tris buffer (0.125 M 
Tris pH6.8, 0.1% SDS), while separating gel was prepared in lower Tris buffer (0.4 M 
pH 8.6, 0.1% SDS). Electrophoretically-separated proteins were transferred from gel 
to a polyvinylidene fluoride (PVDF) membrane (ImmobilonTM-P, Millipore) using 
transfer buffer (50mM Tris Base, 384 mM glycine, 2% methanol and 0.01% SDS) at 
100 volts for 45 minutes to 1 hour depending on the size of the proteins.  After 
transfer, the blot was incubated with blocking solution (1× PBS; 4% non-fat dry milk; 
0.5% Tween 20) for 1 hour, followed by primary antibody staining for 1 hours. 
Thereafter, the blot was washed at least two times (5 minutes each) with the washing 
solution (1× PBS; 0.5% Tween 20) and blocked for 10 minutes in the blocking 
solution.  The blot was then incubated with HRP conjugated secondary antibody for 1 
hour, followed by three washes with washing solution for 15 minutes. Subsequently, 
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the chemiluminescence detection substrate (Pierce) was added onto the blot and the 
proteins were visualized on HyBlotCL® autoradiographyfilms (Denville Scientific 
Inc., Metuchen, NJ).  
 
3.2.2.16 Extraction of total cellular RNA 
 
Total cellular RNA was extracted from various cell lines, using TRIZOL® Reagent 
(Life Technologies, Gaithersburg, MD), according to the manufacturer’s instructions.  
RNA was diluted in 10mM Tris.Cl buffer (pH7.5) and its concentration was 
determined by measuring the absorbance at 260 nm (A260) with a spectrophotometer.  
Only samples with an A260/A280 ratio of 1.9 ~ 2.1 were used for reverse transcription- 
polymerase chain reactions (RT-PCR). 
 
3.2.2.17  Reverse transcription of RNA 
Complementary DNA (cDNA) was prepared from the reverse transcription of five µg 
of the total RNA of each sample.  Five µg of total RNA in a volume of 10 µl was 
mixed with 2 µl of oligo dT (5  µM), 1  µl of dNTP (10mM), 2  µl of DTT (0.1M), 4  
µl of reverse transcriptase buffer (5×) and 1µl of MuMLV reverse transcriptase to 
obtain a final volume of 20 µl.  The reaction mixture was incubated at 42o C for for 1 
hour. A “mock” reverse transcription was done without reverse transcriptase for all 
samples to ensure that there is no DNA contamination in the total RNA extracted for 
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3.2.2.18   Gel electrophoresis of DNA products 
Agarose gels (2%) were prepared in 1×TAE and used to resolve PCR products.  
Following electrophoresis, ethidium bromide-stained DNA was visualized using a 
ultra-violet (UV) trans-illuminator.       
 
3.2.2.19 Real-time quantitative-PCR 
TRIP-Br1, PP2A-Cα and GAPDH cDNA were amplified (in duplicates) in a 25 µl 
Real-time PCR reaction (12.5µl of SYBRGreen mix, 10µl of forward and reverse 
primer at the final concentration of 2.5 µM and 2.5 µl of cDNA), in an iQ5TM real-
time detection system (Bio-rad Laboratories). Real-time quantitative-PCR was 
performed as follows: 40 cycles of denaturation (15 seconds, 95°C), annealing (30 
seconds, 55 °C) and extension (30 seconds, 72 °C) with a 2-minute initial incubation 
step at 50 °C, followed by a 10-minute denaturation step at 95 °C. Thereafter, a 
melting curve analysis was performed, in which the reaction temperature was 
increased gradually (+0.5 °C) from 55.0 °C-95.0 °C in a 30-second interval. Primer3 
software was utilized to facilitate primer design. The following primer sets were used 
and presented from the 5’terminus to the 3’ terminus: human TRIP-Br1 forward: 
aggacctcagccacattgag, human TRIP-Br1 reverse ggtgcccaaagttcattgtc; human 
GAPDH forward: gagtcaacggatttggtcgt, human GAPDH reverse 
ctcagtgtagcccaggatgc; human PP2A-Cα forward: agaattggtggcaaatcacc, human PP2A-
Cα reverse: tgaccacagcaagtcacaca. The fold change in transcript expression of all 
samples was calculated relative to that of GAPDH expression, which was set 
arbitrarily at 1.0. 
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3.2.2.20 Luciferase assays 
 
Transcription activation function of TRP-Br1, in the presence or absence of PP2A-C 
subunit co-transfection was assessed by a dual-luciferase reporter assay kit (Promega, 
Madison, WI), using a Turner TD-20/20 luminometer (Turner biosystem, Sunnyvale, 
CA). Briefly, HK2 cells were transfected with various amounts of the indicated 
expression plasmids, i.e., pCMV-E2F1, pCMV-DP1, a firefly luciferase reporter 
pGL3-TATA6xE2F1-Luciferase, a Renilla luciferase reporter control plasmid pTK-
RL, in the presence or absence PP2A-C subunit expression constructs. Approximately 
2×104 cells were seeded 24 hours before transfection. The total amount of DNA 
transfected was kept constant (0.8 µg) for each well. The cells were washed briefly 
using PBS 48 hours after transfection and lysed with 100 µl of passive lysis buffer. 
The plates were rocked at 200 rpm for 30 min at room temperature. The activity of the 
firefly luciferase was measured using a Turner TD-20/20 luminometer according to 
the manufacturer’s recommendation. Fold activation refers to firefly luciferase 
activity normalized to Renilla luciferase activity and is expressed relative to the 
activity observed with the expression of the experimental reporter (pGL-
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3.3     Results 
 
3.3.1 Identification of the Bα and Bδ subunits of                          
serine/threonine protein phosphatase 2A as novel              
interactors of TRIP-Br1 
 
3.3.1.1 Expression and purification of glutathione S-transferase      
mouse TRIP-Br1 fusion protein 
 
To identify cellular proteins that interact specifically with the TRIP-Br1 proto-
oncoprotein, mouse TRIP-Br1 (mTRIP-Br1) protein fused to Schistosoma japonicum 
glutathione S-transferase was synthesized in Escherichia coli, recovered on 
glutathione agarose and incubated with cell lysates prepared from asynchronously 
growing HEK 293 cells. This approach is a well-established method for identification 
of new proteins that interact with a protein of interest. This method has been used 
successfully to identify retinoblastoma (pRB) interacting proteins (Kaelin et al., 
1991). The expression and purification of the mTRIP-Br1-GST fusion protein is 
shown in the top panel of Figure 3.3.1. Lanes 1-2 and lanes 5-6 represent the total 
protein released from 0.5 ml of broth containing bacteria transformed with the empty 
pGEX vector and pGEX-mTRIP-Br 1, respectively. Total proteins were resolved by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and were visualized using 
Coomassie Blue staining. Upon induction with 0.2 mM IPTG, the expression of both 
GST and GST-mTRIP-Br1 was robust, as shown in lanes 2 and 6. The induced 
proteins in lanes 2 and 4 had apparent molecular weights of 26 and 60 kDa, 
respectively, which were consistent with the expected sizes of GST and GST-mTRIP-
Br1.  When bacterial pellets were sonicated and incubated with glutathione-agarose 
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beads, the induced proteins were reduced substantially in the bacterial lysates, 
suggesting that GST and GST-mTRIP-Br1 bound efficiently to glutathione-agarose 
beads (lanes 3 and 7). The bound proteins were eluted by boiling in an SDS-
containing buffer and were resolved using SDS-PAGE (lanes 4 and 8). The bands 
marked by arrows in lanes 4 and 8 represent the proteins eluted from a 1% solution of 
glutathione-agarose beads incubated with 250 ml of bacterial broth. It was noted that 
the recovery rate of GST-mTRIP-Br1 was significantly lower than that of GST. This 
was probably due to the decreased solubility of the fusion proteins relative to GST. 
This is not unexpected as a similar phenomenon was also reported elsewhere (Kaelin 
et al., 1991). To ensure that the IPTG-induced proteins were the proteins of interest, a 
duplicate gel was run and subjected to Western blotting using a mouse anti-TRIP-Br1 
mouse monoclonal antibody.  The results confirmed that the induced protein with an 
apparent molecular weight of ~ 60 kD was indeed GST-mTRIP-Br1 (Figure 3.3.1, 
middle panel). When the blot was stripped and reprobed for GST, both GST and GST-
mTRIP-Br1 were detected (Figure 3.3.1, bottom panel), demonstrating that the 
purified proteins were GST and GST-mTRIP-Br1. 
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Figure 3.3.1: Expression and purification of glutathione S-transferase 
mTRIP-Br1 fusion protein. 
Lane 1: Total protein released from 0.5 ml of pGEX transformed bacteria before 
induction; Lane 2: Total protein released from 0.5 ml pGEX transformed bacteria 
after IPTG induction; Lane 3: Total protein after incubation of IPTG-induced pGEX 
transformed bacterial lysate with glutathione-agarose beads; Lane 4: Purified GST 
protein after elution; Lane 5: Total protein released from 0.5 ml of pGEX-mTRIP-Br1 
transformed bacteria before induction; Lane 6: Total protein released from 0.5 ml 
pGEX-mTRIP-Br1 transformed bacteria after IPTG  induction; Lane 7: Total protein 
after the incubation of IPTG-induced pGEX-mTRIP-Br1 transformed bacteria with 
glutathione-agarose beads; Lane 8: Purified GST-mTRIP-Br1 protein after elution. 
The small arrow () indicates GST protein. The large arrow () indicates GST-
mTRIP-Br1 protein. The gel in the upper panel was stained with Coomassie Blue. A 
duplicate gel was probed with antibodies against TRIP-Br1 (middle panel) and GST 
(lower panel).  
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3.3.1.2  Probing mammalian cellular protein extracts with GST-
mTRIP-Br1 
 
The above purified GST-mTRIP-Br1 and GST proteins were used to probe human 
HEK 293 cell lysates for TRIP-Br1 interactors. HEK 293 cell line was selected for 
use here because of its low endogenous levels of TRIP-Br1 protein, which minimizes 
competition for binding with potential interactors of the GST-TRIP-Br1 fusion protein 
(Figure 3.3.2).  TRIP-Br1 is highly conserved across vertebrate species.  Human and 
mouse TRIP-Br1 sequences possess about 87% identity and 96.6% similarity. 
Considering the high degree of homology between the mouse and human TRIP-Br1 
proteins, we reasoned that GST-mTRIP-Br1 would be recognized by potential 
interactors of human TRIP-Br1.  After incubation with HEK 293 whole cell lysates, 
GST-mTRIP-Br1 or GST bound to agarose beads were intensively washed. The 
bound proteins were eluted from the glutathione agarose beads, resolved by SDS-
PAGE and visualized by silver staining (Figure 3.3.3).  Lanes 1 and 3 represent the 
purified GST () and GST-mTRIP-Br1 () eluted from the glutathione agarose 
beads.  Lanes 2 and 4 represent the total protein eluted from GST and GST-mTRIP-
Br1 glutathione agarose beads, respectively, following incubation with HEK 293 
whole cell lysates. Thus any band observed in lane 4 but absent in lanes 1, 2 and 3 
may potentially contain proteins that bind to TRIP-Br1. One distinct and unique band 
was observed in lane 4 at about 55 kD, as indicated by (). This band was completely 
absent in the other three lanes despite the use of a high concentration of GST when 
probing the cell lysates. This suggests that proteins contained in this band may 
specifically bind to TRIP-Br1 protein in HEK 293 cells.  
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Figure 3.3.2:    Endogenous TRIP-Br1 expression in a panel of 
human kidney epithelial cell lines.  
Sub-confluent 786-O (human kidney clear cell carcinoma cell line), 769-P (human 
kidney clear cell carcinoma cell line), HEK 293 (human embryonic kidney epithelial 
cell line) and HK2 (human adult kidney epithelial cell line) cells were lysed and 
subjected to western blotting.  Fifty micrograms of total protein were loaded and 
probed with anti-TRIP-Br1 mouse monoclonal antibody. β-Tubulin was used as 
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-                         
 
Figure 3.3.3:  Visualization of GST-mTRIP-Br1-bound proteins in 
HEK 293 cellular extracts by silver staining. 
Lane 1: Purified GST () eluted from glutathione agarose beads; Lane 2: Bound 
proteins eluted from GST glutathione agarose beads after incubation with HEK 293 
whole cell lysates; Lane 3: Purified GST-mTRIP-Br1 () eluted from glutathione 
agarose beads; Lane 4: bound proteins eluted from GST-mTRIP-Br1 glutathione 
agarose beads after incubation with HEK 293 whole cell lysates in RIPA buffer. The 
arrow () indicates the unique band that appeared after GST-mTRIP-Br1 glutathione 
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3.3.1.3  Mass spectrometric analysis 
The unique band labeled as () in Figure 3.3.3 was excised from the gel and sent for 
in-gel digestion and mass spectrometric analysis.   The five proteins identified in that 
band are presented in Table 3.2, ranked according to the number of matching 
peptides. All of the proteins in Table 3.2 satisfied the requirement of having at least 
two strongly matched peptides, as determined by the database-searching program 
Sequest along with manual inspection of the data.  The peptides that were identified 
by LC/MS and mapped to Bα and Bδ of PP2A were listed in Figure 3.3.4. 
 
Among these five proteins, two proteins that belong to the regulatory B subunits of 
serine/threonine-protein phosphatase 2A (PP2A) are particularly noteworthy for two 
reasons. Firstly, to date, numerous cell cycle-related proteins and transcription factors 
have been shown to interact with PP2A including c-Myc, securin, STAT 3, p53 and 
cdc6. Secondly, identification of the two PP2A-B isoforms, PP2A-Bα and PP2A-Bδ, 
which belong to the same family of regulatory B subunits and share high sequence 
homology, suggests that these proteins may not have been pulled down non-
specifically by the GST-mTRIP-Br1 affinity binding assay. At least four families of 
PP2A-B subunits have been identified in eukaryotes to date, denoted B/PR55 (Bα, Bβ, 
Bγ, Bδ), B'/PR61 (B'α, B'β, B'γ, B'δ), B'' (PR72, PR130, PR48, PR59) and B''' (PR93, 
PR110). However, there is little sequence homology among the different 
submembers.  Analysis of the human PP2A-Bα and PP2A-Bδ sequences using 
ClustalW revealed a high degree of homology (88% identity and 95% similarity), 
suggesting these subunits may share a subset of interactors (Figure 3.3.5). Similar 
results have been reported by Seeling et al. who identified the α and δ isoform of the 
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B' subfamily of PP2A regulatory subunits as adenomatous polyposis coli (APC) 
interactors using the NH2-terminal third of APC as a bait in a two-hybrid screen 
(Seeling et al., 1999).  Based on the above preliminary results and rationale, we 
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Table 3.2: The proteins identified from the unique 55 kD band by 
liquid chromatography/mass spectrometry. 
  
















 Serine/threonine-protein phosphatase 2A  
55 kDa regulatory subunit Bα isoform 










ATP synthase subunit β, mitochondrial 









Tubulin α-2 chain Q13748 49960 5 14.90% 
  
Serine/threonine-protein phosphatase 2A 
55 kDa regulatory subunit Bδ isoform 













Tubulin α-6 chain Q9BQE3 49895 2 5.60% 
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Figure 3.3.4:  The identified peptides (highlighted in green) by liquid 
chromatography/mass spectrometry. 
 
Mass spectrometry sequences are shown for peptides derived from a 55 kD band 
appearing in a GST-mTRIP-Br1 pull-down in HEK 293 cells.  The highlighted 




    
 
 
                                                     A      
 
                                              B                            
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Figure 3.3.5: Alignment of the protein sequences of PP2A-B family 
members, Bα and Bδ. 
 
Sequence alignment with ClustalW reveals 88% identity and 95% similarity between 
PP2A-Bα and PP2A-Bδ. There is no sequence homology between PP2A-Bα or Bδ 
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3.3.2 TRIP-Br1 associates with catalytically active PP2A            
holoenzyme in vitro 
  
3.3.2.1  GST-mTRIP-Br1 binds to the PP2A holoenzyme comprising  
the A/Bα /C subunits 
 
To verify that PP2A-Bα indeed associates with TRIP-Br1 in vitro, pre-cleared lysates 
from HEK 293 cells were incubated with glutathione agarose beads pre-loaded with 
GST-mTRIP-Br1 or GST. After washing the beads, bound proteins were 
electrophoresed, transferred to a nitrocellulose membrane, and probed with anti-
PP2A-Bα rabbit anti-human monoclonal antibody (Figure 3.3.6). The PP2A-Bα 
subunit was readily detected in the GST-mTRIP-Br1 pull-down, whereas it was not 
pulled down by GST. As PP2A holoenzyme is composed of a scaffold A subunit, a 
catalytic C subunit and a regulatory B subunit, we tested whether GST-mTRIP-Br1 
fusion protein associates with the PP2A-C subunit. The bound proteins were resolved 
for immunodectection of the PP2A-C subunit. Figure 3.3.6 shows that the PP2A-C 
subunit was detected among GST-mTRIP-Br1 bound proteins but not among GST-
bound proteins. 
 
To validate this observation in other cell lines, a GST pull-down assay was conducted 
with whole cell lysate extracted from 769-P cells, another cell line with low 
endogenous TRIP-Br1 protein expression level (Figure 3.3.2).  The same results 
found in HEK 293 cells were reproduced using 769-P cell extracts. The protein 
complex comprising the PP2A-A/Bα/C subunits was pulled down by GST-mTRIP-
Br1, but not by GST alone (Figure 3.3.7). The amount of purified GST and GST-
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mTRIP-Br1 protein employed in this pull-down assay was visualized using 
Coomassie Blue staining. 
 
Our data suggest that the PP2A-C is indeed detectable from the protein complex that 
is consists of GST-TRIP-Br1 and PP2A-Bα. However, the amount of the PP2A-C 
protein associated with GST-TRIP-Br1 is always less comparing to PP2A-Bα, in 
multiple independent experiments using different cellular extract (293 and 769-P 
cells). This result is consistent with a model in which PP2A-C protein exists in a 
complex with the PP2A-Bα subunit, but that only the PP2A- Bα interacts directly with 
TRIP-Br1. This suggests a model in which PP2A-C protein forms a complex with 
TRIP-Br1 “indirectly” through PP2A-Bα subunit. Considering the protein-protein 
interaction usually is very fragile (thus routinely conduct at 4ºC), it is logical that 
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Figure 3.3.6:   GST-mTRIP-Br1 fusion protein pulls down PP2A 
holoenzyme in HEK 293 cells in vitro.  
Glutathione agarose beads preloaded with GST or GST-mTRIP-Br1 were incubated 
with 1 mg of HEK 293 cell lyaste in RIPA buffer. The bound proteins were washed, 
eluted and resolved by SDS-PAGE for immunodetection of PP2A-Bα and PP2A-C.  
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Figure 3.3.7: GST-mTRIP-Br1 pulls down the PP2A holoenzyme 
comprising the A/Bα/C subunits in 769-P cells in vitro. 
 
Glutathione agarose beads preloaded with GST or GST-mTRIP-Br1 were incubated 
with 1 mg of 769-P cell lyaste in RIPA buffer. The bound proteins were washed and 
eluted from the beads, resolved by SDS-PAGE and probed with anti-PP2A-Bα rabbit 
monoclonal antibodies, anti-PP2A-C mouse monoclonal antibodies and anti-PP2A-A 
polyclonal antibodies.  The amount of purified GST and GST-mTRIP-Br1 protein 
used in the pull-down assay was visualized by Coomassie Blue staining. Five percent 
of the 769-P cell lysate was run in parallel as a control. The small arrow () indicates 
GST protein. The large arrow () indicates GST-mTRIP-Br1 protein. 
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3.3.2.2  Catalytically active PP2A holoenzyme associates with  GST- 
             mTRIP-Br1  
 
To determine whether the PP2A holoenzyme pulled down by GST-mTRIP-Br1 was 
catalytically active, the 769-P cellular proteins that bind to GST-mTRIP-Br1 fusion 
protein were incubated with a chemically synthesized PP2A phosphopeptide 
substrate. The amount of phosphate released was measured using a quantitative non-
radiometric assay. Phosphatase activity was 7-fold greater among proteins pulled 
down by GST-mTRIP-Br1 than among those pulled down by GST (Figure 3.3.8a). 
Significant phosphatase activity was also detected among cellular proteins in the 
GST-mTRIP-Br1 pull-down from HEK 293 cells (data not shown).   
 
To test whether the phosphatase activity detected in the GST-mTRIP-Br1 pull-down 
was sensitive to inhibition, okadiac acid (OA), a PP2A inhibitor isolated from the 
marine sponge, Halichondria okadai, was added to the enzymatic reaction (Sontag, 
2001; Sontag et al., 1995). About 70% of the phosphatase activity in the GST-mTRIP-
Br1 pull-down was inhibited upon treatment with 10 nM of OA (Figure 3.3.8b). 
Together, these data strongly suggest that PP2A-A/Bα/C holoenzyme not only 
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Figure 3.3.8a:   GST-mTRIP-Br1 pulls down catalytically active 
PP2A.  
 
Proteins pulled down by GST or GST-mTRIP-Br1 from 769-P cells were tested for in 
vitro phosphatase activity. Phosphatase activity is presented relative to that observed 














Figure 3.3.8b:   Catalytically active PP2A pulled down by GST-
mTRIP-Br1 is sensitive to okadaic acid. 
 
GST or GST-mTRIP-Br1 pull-down from HEK 293 cell extracts were used for in 
vitro phosphatase assay in the presence or absence of 10 nM of okadaic acid. 
Phosphatase activity is presented relative to that observed in GST control pull-down 
without okadaic acid treatment (set arbitrarily as 1-fold activity). Similar results were 
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3.3.3   Endogenous human TRIP-Br1 associates with PP2A 
holoenzyme in vivo 
 
To assess the association between TRIP-Br1 and PP2A in a physiological setting, 
endogenous TRIP-Br1 protein was immunoprecipitated with anti-TRIP-Br1 
monoclonal antibody from sub-confluent HK2 cells (normal human adult proximal 
tubular cell line).  Mouse IgG was included as a negative control for 
immunoprecipitation.  HK2 cells were chosen because endogenous TRIP-Br1 is 
abundant in this cell line (Figure 3.3.2). Following immunoprecipitation, the proteins 
were resolved and the blot was probed with anti-PP2A-Bα rabbit monoclonal 
antibody. The results demonstrated endogenous TRIP-Br1 and PP2A-Bα exist in the 
same complex in this human cell background (Figure 3.3.9).  Similar to what was 
observed in the GST pull-down assays, the PP2A-C s0ubunit was also detected in the 
TRIP-Br1 immunoprecipitates. In contrast, no subunits of the PP2A holoenzyme were 
present in the mouse IgG control immunopreciation. The same observation was also 
made in 786-O cells, a human kidney clear cell carcinoma cell line with high 
endogenous expression levels of TRIP-Br1, further confirming that endogenous Bα 
subunit of PP2A and TRIP-Br1 exist in the same complex in untransfected 
mammalian cells (Figure 3.3.10). 
                
Notably, the amount of endogenous PP2A-Bα and PP2A-C protein that co-
immunoprecipated with endogeneous TRIP-Br1 is relatively small. However, it is not 
expected that every molecule of endogenous TRIP-Br1 protein is associated with 
PP2A in vivo. As PP2A functions to remove phosphate groups from serine and 
threonine residues of target substrates, PP2A may only bind to the phosphorylated 
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form of TRIP-Br1 to carry out regulated dephosphorylation. . It has been known that 
phosphrylations only take place in a small fraction of the protein under normal 
circumstances. Consistent with our result, the interaction between TRIP-Br1 protein 
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Figure 3.3.9: Endogenous PP2A holoenzyme co-immunoprecipitates 
with endogenous TRIP-Br1 protein in HK2 cells. 
 
Endogenous TRIP-Br1 protein was immunoprecipitated from HK2 cells with anti-
TRIP-Br1 mouse monoclonal antibody. The immunoprecipitates were probed for 
PP2A-Bα and PP2A-C protein with specific antibodies.  The blot was stripped and 
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Figure 3.3.10: Endogenous PP2A holoenzyme co-immunoprecipitates 
with endogenous TRIP-Br1 protein in 786-O cells.  
 
Endogenous TRIP-Br1 protein was immunoprecipitated from 786-O cells with anti-
TRIP-Br1 mouse monoclonal antibody. Immunoprecipitated proteins (IP) and protein 
extracts used for the immunoprecipitation (Input) were subjected to SDS-PAGE and 
Western blot analysis. Presence of the PP2A-Bα, PP2A-C and PP2A-A protein 
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3.3.4  Endogenous TRIP-Br1, a cytoplasmic dominant 
protein,  co-localizes with the Bα subunit of PP2A 
 
To determine whether PP2A-Bα co-localizes with TRIP-Br1 to facilitate the physical 
contact between these two molecules in intact mammalian cells, immunofluorescence 
staining of endogenous TRIP-Br1 was performed on untransfected 786-O cells. 
Notably, endogenous TRIP-Br1 protein was predominately expressed in the 
cytoplasm of 786-O cells, although some staining was also found in the nuclei (Figure 
3.3.11). This result contradicts previous reports that exogenous epitope-tagged TRIP-
Br1 protein mainly localizes to the nucleus based on immunofluorescence staining of 
overexpressed epitope-tagged exogenous TRIP-Br1 protein and the pattern of GFP-
TRIP-Br1 fusion protein expression (Lai et al., 2007; Sugimoto et al., 1999).  
 
To confirm the subcellular localization of endogenous TRIP-Br1 protein, 
asynchronized 786-O and HK2 cells were divided into nuclear and cytosolic fractions 
using a commercial kit.  The expression of endogenous TRIP-Br1 in these two cell 
lines is reasonably abundant to facilitate the immunodetection of the protein. 
Immunodetection of endogenous PP2A-Bα and TRIP-Br1 protein from the nuclear 
and cytosolic fractions was conducted.  In agreement with what was observed in 
immunofluorescence staining, endogenous TRIP-Br1 was predominately detected in 
the cytosolic fraction of the two cell lines (Figure 3.3.12).  Relatively little TRIP-Br1 
was detected in the nuclear fraction of the cell lines. Consistent with previous reports, 
PP2A-Bα was mainly localized to the cytosol (De Baere et al., 1999; Sontag et al., 
1995; Strack et al., 1998). GAPDH, a cytosolic protein, and Lamin B, a nuclear 
envelope protein, were immunodetected to verify the purity of the nuclear and 
cytosolic fractions. A small amount of GAPDH protein was detected in the nuclear 
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fraction, likely due to minor contamination between the nuclear and cytosolic 
fractions, a common problem encountered in subcellular fractionation techniques. 
However, this does not change the interpretation of the data that endogenous PP2A-
Bα and TRIP-Br1 are predominantly expressed in the cytoplasm.  These results 
suggest that endogenous PP2A-Bα and TRIP-Br1 locate at the same cellular 
compartments.  
 
To confirm the above observation in non-cancerous and non-transformed mammalian 
cells, normal human and mouse fibroblast WI38 and NIH3T3 cells were subjected to 
subcellular fractionation and TRIP-Br1 immunodetection.  Endogenous TRIP-Br1 
proteins were predominantly found in the cytosolic fraction in both of the normal 
fibroblast cell lines (Figure 3.3.13). 
 
To make certain that our observation was not an “antibody artifact,” the specificity of 
the anti-TRIP-Br1 monoclonal antibody used for the localization study was re-
examined. 769-P cells, which have very low endogenous TRIP-Br1 expression levels, 
were infected with adenovirus-encoding GFP or FLAG-TRIP-Br1. The cells were 
harvested at 48 hours post-transfection and subjected to Western blot analysis. A 
specific band at 34-40 kD corresponding to FLAG-TRIP-Br1 was detected in the 
lysate from Ad-FLAG-TRIP-Br1- infected cells but not in lysate from Ad-GFP-
infected cells (Figure 3.3.14). No other bands were detected with this antibody. In 
addition, this antibody was able to specifically detect the purified GST-mTRIP-Br1 
protein produced by transformed bacteria (Figure 3.3.1). Moreover, it has been 
previously observed that peptide blocking before immunodetection completely 
abolishes the TRIP-Br1 band (data not shown). Thus, the anti-TRIP-Br1 mouse 
Zhijiang Zang  Medicine, NUS 
PhD. Thesis  2003-2007 
    
               122
monoclonal antibody used here is specific, and the expression pattern of endogenous 
TRIP-Br1 observed in the immunofluorescence staining and subcellular fractionation 
experiment is consistent.  
 
Since previous reports of a predominant nuclear localization of TRIP-Br1 is based 
exclusively on studies employing the overexpression of exogenous tagged TRIP-Br1 
protein, we then conducted immunofluorescence staining on cells expressing 
exogenous TRIP-Br1. Adenovirus-encoding, FLAG-tagged TRIP-Br1 was used to 
infect 769-P cells. Twenty-four hours after infection, the cells were subjected to 
immunofluorescence staining using anti-FLAG antibody. Indeed, FLAG-TRIP-Br1 
was exclusively localized to the nucleus of the cells (Figure 3.3.15). Similar results 
were also observed in the case of HA-TRIP-Br1 with anti-HA antibody when COS7 
cells were transiently transfected with the expression construct pcDNA-HA-TRIP-Br1 
(Figure 3.3.16). Based on all of the above observations, we conclude that endogenous 
TRIP-Br1 protein is mainly expressed in the cytoplasm with some nuclear expression, 
while overexpressed exogenous tagged TRIP-Br1 protein is exclusively expressed in 
nucleus. It is known that tagging or overexpression can potentially alter the 
intracellular localization or function of target proteins (Miyashita, 2004). 
 
To assess whether endogenous TRIP-Br1 and PP2A-Bα proteins co-localize in vivo to 
facilitate interaction, a co-localization study was conducted on untranfected HK2 and 
786-O cells by dual staining of endogenous TRIP-Br1 and PP2A-Bα. Consistent with 
what has been previously observed, the distribution of endogenous TRIP-Br1 was 
primarily cytosolic with some staining in the nucleus. PP2A-Bα was found mainly in 
the cytoplasm as well. When the images from the two channels were merged, the two 
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molecules appeared to co-localize in the cytoplasm and in the nucleus, although the 
staining intensity was lower in nucleus (Figure 3.3.17).  
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Figure 3.3.11:  Subcellular localization of endogenous TRIP-Br1 in 
786-O cells. 
 
 Untranfected 786-O cells were fixed with 4% of paraformaldehyde in PBS and 
immunostained with anti-TRIP-Br1 mouse monoclonal antibody, followed by 
fluorescence microscopy analysis. (Left) DAPI staining; (Center) TRIP-Br1 staining; 
(Right) merged image.         
 
                                 
Figure 3.3.12: Subcellular fractionation indicates a predominantly 
cytoplasmic distribution of endogenous TRIP-Br1 and PP2A-Bα 
protein in HK2 and 786-O cells.  
 
The nuclear and cytosolic fractions of lysates from HK2 and 786-O cells were 
prepared and immunoblotted for TRIP-Br1 and PP2A-Bα. GAPDH and Lamin B 
were used as cytoplasmic and nuclear markers, respectively. 
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Figure 3.3.13: Endogenous TRIP-Br1 protein mainly expresses in the  
cytosolic fraction of NIH3T3 and WI38 cells.  
The nuclear and cytosolic fractions of lysates from NIH3T3 and WI38 cells were 
prepared and immunoblotted for TRIP-Br1. GAPDH and Lamin B were used as the 
cytoplasmic and nuclear markers, respectively. 
 
                                                       
Figure 3.3.14: Specificity of the anti-TRIP-Br1 mouse monoclonal 
antibody.  
 
Ad-GFP- or Ad-FLAG-TRIP-Br1-infected 769-P cells were subjected to western blot 
analysis. The blot was simultaneously stained with anti-TRIP-Br1 and anti-β-Tubulin 
antibody. 
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Figure 3.3.15: Viral vector-encoded FLAG-TRIP-Br1-GFP protein 
expresses in the nucleus of 769-P cells.  
769-P cells infected with adenovirus-encoding FLAG-TRIP-Br1-GFP were fixed with 
4% paraformaldehyde in PBS, stained with FLAG antibody and visualized using 





                        
   
Figure 3.3.16: Exogenous HA-TRIP-Br1 protein expresses in the 
nucleus of cos7 cells.  
 
Cos7 cells transfected with pcDNA-HA-TRIP-Br1 were fixed with 4% 
paraformaldehyde in PBS and immunostained with anti-HA antibody (Left: DAPI 
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Figure 3.3.17:  PP2A-Bα and TRIP-Br1 co-localize predominantly in 
the cytoplasm, with co-staining in nucleus of HK2 and 786-O cells.  
 
HK2 and 786-O cells were fixed with 4% of paraformaldehyde in PBS and double- 
stained with PP2A-Bα and TRIP-Br1 antibody (Left: TRIP-Br1; Center: PP2A-Bα; 
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3.3.5   TRIP-Br1 is a serine-phosphorylated protein 
Next, we sought to investigate the significance of PP2A-A and TRIP-Br1 interaction. 
As the function of PP2A is to remove phosphate from serine/threonine residues of 
phosphoprotein substrates, the possibility that TRIP-Br1 is serine or threonine 
phosphorylated was explored. Bioinformatics tools were utilized to analyze the full-
length sequence of human TRIP-Br1 protein to determine whether any 
phosphorylatable serine or threonine residues were present. Netphos 2.0 is a 
commonly used server that predicts eukaryotic protein phosphorylation sites based on 
experimentally verified phosphorylation sequences as reported in the literature or in 
curated databases such as the Swiss-Prot database (Blom et al., 1999; Blom et al., 
2004). Seven serine residues and 1 tyrosine site in the human TRIP-Br1 sequence 
were predicted to be potentially phosphorylated by the bioinformatics analysis of full-
length TRIP-Br1 protein sequence using this software (Figure 3.3.18A). In contrast, 
no threonine residues were identified as potential targets for phosphorylation. The 
predicted serine sites, consensus sequences and scores are listed in Figure 3.3.18B. 
ClustalW (version 1.83) multiple sequence alignment showed that all of these sites are 
conserved across mammalian species, including humans, chimpanzees, monkeys, 
cattle and rats (data not shown).   
 
The above prediction encouraged us to assess whether TRIP-Br1 is a serine 
phosphorylated protein using experimental methods.  Endogenous human TRIP-Br1 
was immunoprecipitated from HK2 cells using anti-TRIP-Br1 monoclonal antibody. 
Protein A/G beads were used as a negative control.   The immunoprecipitates were 
resolved by SDS-PAGE and probed with anti-phosphoserine antibody. As shown in 
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Figure 3.3.19 (Left panel), a band at 34 kD was noted in the lane containing the TRIP-
Br1 immunoprecipitates. When the blot was stripped and reprobed with anti-TRIP-
Br1 antibody, the phosphoserine band overlapped with the TRIP-Br1 band (Figure 
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Figure 3.3.18: Predicted phosphorylation sites on full-length human 
TRIP-Br1 protein. 
 
(A) Potentially phosphoryled serine, threonine and tyrosine residues on TRIP-Br1 
protein as predicted by the program Netphos 2.0. (B) The predicted serine 
phosphorylated sites, concensus sequences and prediction scores for each serine 
residue on TRIP-Br1. 
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Figure 3.3.19: Endogenous TRIP-Br1 protein is a serine-
phosphorylated protein. 
 
Endogenous TRIP-Br1 was immunoprecipitated from HK2 cells. The 
immunoprecipated proteins were subjected to SDS-PAGE and immunodetection of 
phophoserine residues (Left panel). The blot was stripped and reprobed with TRIP-
Br1 antibody (Right panel). Arrow () indicates serine-phosphorylated TRIP-Br1 
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3.3.6   Okadaic acid treatment alters the level of serine-
phosphorylated and total TRIP-Br1 protein  
   
The observation that TRIP-Br1 is a serine-phosphorylated protein, together with the 
finding that PP2A holoenzyme physically associates with TRIP-Br1, strongly 
suggested that TRIP-Br1 may serve as a substrate of PP2A.  To examine the effect of 
PP2A-mediated TRIP-Br1 dephosphorylation, we treated HK2 cells with okadiac acid 
(OA), a potent cell-membrane-permeable toxin that specifically inhibits 
serine/threonine protein phosphatase 2A and protein phosphatase 1. Five hundred nM 
and 1 µM of OA were used to treat HK2 cells for 1 hour. It has been shown that about 
50% and 90% of PP2A activity was inhibited in vivo by 0.5 and 1 µM of OA, 
respectively (Sun et al., 2007). As demonstrated in Figure 3.3.20, OA treatment 
resulted in decreased endogenous TRIP-Br1 protein levels. Endogenous c-Myc 
protein was probed as a positive control because it is well-established that c-Myc is a 
substrate of PP2A, and OA treatment causes accumulation of c-Myc protein by 
inhibiting PP2A mediated-dephosphorylation of c-Myc (Arnold and Sears, 2006; Yeh 
et al., 2004). In line with the literature, we also observed that c-Myc protein 
accumulated upon treatment with OA. When endogenous TRIP-Br1 protein was 
immunoprecipitated and probed with anti-phosphoserine antibody, an enhanced 
serine-phosphorylated form of TRIP-Br1 was detected in OA-treated cells, as 
compared with vehicle-treated cells. Similar results were also obtained with 786-O 
cells (data not shown).  The effect on endogenous TRIP-Br 1 protein levels upon OA 
treatment is in agreement with that of known PP2A cellular substrates such as Bcl-2 
and securin, suggesting that PP2A may associate with TRIP-Br1 in vivo and 
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dephosphorylate the serine-phosphorylated form of TRIP-Br1 (Gil-Bernabe et al., 
2006; Lin et al., 2006; Ruvolo et al., 2002).  
 
As it has been documented that PP2A may regulate the subcellular distribution of 
some of its substrates such as STAT3 by dephosphorylation, the possibility of PP2A-
mediated TRIP-Br1 nuclear import/export was also explored (Woetmann et al., 1999).   
HK2 cells were treated with 1 µM of OA or vehicle for 1 hour. The cytosolic and 
nuclear fraction was obtained from the OA- or vehicle-treated cells. Immunoblotting 
for endogenous TRIP-Br1 and β-Tubulin showed that OA treatment did not change 
the subcellular distribution of TRIP-Br1 protein (Figure 3.3.21).  This result indicates 
that the subcellular distribution of TRIP-Br1 is not likely to be regulated by PP2A-
mediated dephosphorylation.  
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Figure 3.3.20: Okadaic acid treatment increases the level of serine-
phosphorylated TRIP-Br1 but decreases the level of total TRIP-Br1 
protein. 
 
(A) HK2 cells were treated with vehicle, 0.5 or 1 µM of okadaic acid for 1 hour. The 
total protein was probed for TRIP-Br1, c-Myc and β-Tubulin with the specific 
antibodies. (B) A quantitative analysis of TRIP-Br1 protein level in okadaic acid 
(OA) treated cells compared to that of vehicle treated cells.  Antibody signals were 
quantitatively analyzed using Genetools (Syngene, Frederick, MD).  Quantitated 
TRIP-Br1 protein levels were first normalized to loading control (β-tubulin) protein 
levels. The amount of TRIP-Br1 in OA-treated cells relative to that of vehicle treated 
cells, which were set to one fold or 100% as indicated, was then calculated. Average 
protein levels and error bars representing standard deviations were calculated from 
three independent experiments using Excel. (C) HK2 cells were treated with 1 µM of 
okadaic acid for 1 hour. Endogenous TRIP-Br1 protein was immunoprecipitated and 
probed for the presence of phosphorylated serine residues by anti-phosphoserine 
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Figure 3.3.21: Okadaic acid treatment does not change the 
subcellular distribution of TRIP-Br1. 
 
HK2 cells were treated with 1 µM of okadaic acid for 1 hour. Proteins from the 
cytosolic and nuclear fraction of the cell lysates were subjected to SDS-PAGE and 
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3.3.7  Transcriptional silencing of the PP2A catalytic  
subunit decreases the level of TRIP-Br1 protein   
 
To demonstrate that the effect of OA treatment on TRIP-Br1 in HK2 cells was 
specifically attributable to PP2A inhibition, transcriptional silencing of the PP2A 
catalytic subunit was achieved by transfecting HK2 cells with siRNA targeting PP2A. 
Forty-eight hours after transfection, cells were lysed, and the total proteins were 
subjected to SDS-PAGE and immunodetection of PP2A-C and TRIP-Br1. It showed 
that the expression of endogenous PP2A-C protein in HK2 cells was dramatically 
suppressed by PP2A-C siRNA transfection, compared with the scramble siRNA 
control. Similar to OA treatment, inhibition of PP2A expression by PP2A-C siRNA 
silencing significantly decreased endogenous TRIP-Br1 protein (Figure 3.3.22).   
 
The decreased endogenous TRIP-Br1 protein level upon transcriptional silencing of 
the PP2A catalytic subunit gene may have been due to a resultant decrease in the 
serine dephosphorylation of the TRIP-Br1 protein by PP2A, or to the direct effect of 
decreased TRIP-Br1 transcript.  To exclude the latter possibility, the effect of PP2A-
siRNA on the levels of TRIP-Br1 mRNA was determined. HK2 cells were harvested 
36 hours after siRNA transfection for total RNA extraction. The RNA was 
quantitated, and an equal amount of mRNA was reverse-transcribed. Real-time PCR 
was conducted to compare the transcript levels of endogenous PP2A-C and TRIP-Br1 
in the PP2A-C and the control siRNA-treated cells. Consistent with what we have 
found at the protein level, PP2A-C siRNA treatment resulted in about 80% 
downregulation in the expression of PP2A-C subunit mRNA, as compared to the 
control (Figure 3.3.23A).  However, the level of endogenous TRIP-Br1 mRNA 
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remained constant (Figure 3.3.23B), confirming that the effect of PP2A-C siRNA on 
the endogenous level of TRIP-Br1 protein is not due to an inadvertent effect of PP2A 
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Figure 3.3.22: Knocking down PP2A-C subunit decreases the level of 
TRIP-Br1 protein.  
 
HK2 cells were transfected with negative control siRNA or PP2A-C siRNA. Total 
protein was harvested 48 hours after the transfection and probed for PP2A-C, TRIP-
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Figure 3.3.23: Knocking down PP2A-C subunit does not alter the 
level of TRIP-Br1 mRNA expression. 
 
HK2 cells were transfected with negative control siRNA or PP2A-C siRNA. Total 
RNA was harvested 36 hours after the transfection. PP2A-C and TRIP-Br1 mRNA 
were evaluated by real-time PCR. (A) The expression level of PP2A-C and TRIP-Br1 
mRNA in PP2A-C siRNA-treated cells relative to control siRNA-treated cells. 
GAPDH mRNA was used as a loading control. All experiments were performed in 
duplicate. (B) Agarose gel analysis of PCR products to confirm the presence of the 
specific amplicons. 
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3.3.8  Overexpression of the PP2A-C subunit increases the 
level of TRIP-Br1 protein and TRIP-Br1 co-activated 
E2F1/DP1 transcription 
 
To further characterize the role of PP2A in regulating endogenous TRIP-Br1 protein, 
the effects of increasing cellular PP2A expression on TRIP-Br1 protein levels was 
assessed by transient transfection of expression constructs encoding the PP2A-A, -Bα, 
and -C subunits into HK2 cells.  Forty-eight hours post-transfection, the cells were 
lysed, and the total proteins were resolved by SDS-PAGE.  Western blot analysis 
using antibodies against the PP2A-A, -Bα, and -C subunits was conducted in order to 
compare the relative expression of exogenous and endogenous protein. Figure 3.3.24 
shows that expression levels of the exogenous PP2A-A and -C subunits were 3 to 4 
times higher than the endogenous proteins, while only about 20 to 30% more PP2A-
Bα subunit was overexpressed upon transient transfection.  Endogenous TRIP-Br1 
levels increased with the overexpression of the PP2A-C subunit, but not with the 
overexpression of the A or Bα subunits. While the lack of effect of Bα expression on 
TRIP-Br1 may be due to insufficient overexpression of the Bα subunit, the absence of 
effect of the A subunit may suggest that the scaffolding subunit is not a limiting factor 
for PP2A-mediated regulation of TRIP-Br1. As a positive control, securin was probed 
simultaneously with TPIP-Br1, since securin has been demonstrated to accumulate 
when PP2A-C is overexpressed (Gil-Bernabe et al., 2006). 
 
To exclude the possibility that the observed effect of PP2A-C on TRIP-Br1 was due 
to increased TRIP-Br1 mRNA levels, quantitative PCR analysis was performed. Total 
RNA was isolated 36 hours after transfection, and subjected to reverse transcription 
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and real-time PCR analysis.  Real-time PCR quantitatively confirmed the 
overexpression of PP2A-C mRNA, which was 16-fold higher in cells transfected with 
a P2A-C expression construct compared to vector-transfected cells. The TRIP-Br1 
mRNA level did not increase with the overexpression of PP2A-C (Figure 3.3.25A). 
The PCR products were also analyzed by agarose gel to confirm the presence of the 
specific amplicons (Figure 3.3.25B).  
 
To confirm that the upregulation of TRIP-Br1 in PP2A-C-overexpressing cells was 
due to PP2A-mediated dephosphorylation, endogenous TRIP-Br1 protein was 
immunoprecipitated from PP2A-C- or vector-transfected HK2 cells and probed with 
anti-phosphoserine antibody. Decreased phosphoserine signals were found in TRIP-
Br1 proteins immunoprecipitated from the PP2A-C-overexpressing cells, as compared 
to controls (Figure 3.3.26, Left panel), despite more TRIP-Br1 being pulled down 
from the PP2A-C-transfected cell lysate (Figure 3.3.26, Right panel). 
 
TRIP-Br1 is a PHD zinc finger- and bromodomain-interacting protein that co-
activates the transcriptional activity of E2F1/DP1. Thus, we asked whether the 
increase in TRIP-Br1 protein observed upon overexpression of PP2A-C had 
functional significance. To assess TRIP-Br1 co-activated E2F1/DP1 transcription, a 
firefly luciferase reporter plasmid bearing an artificial 6×E2F1 binding site, pGL3-
TATA6×E2F1, was transiently co-transfected with Renilla luciferase plasmid pRL-
TK as an internal control. Consistent with previous reports, co-transfection of TRIP-
Br-1 with E2F1/DP1 expression constructs stimulated the E2F1-Luc reporter activity 
significantly (Figure 3.3.27).  When a PP2A-C expression construct was co-
transfected with TRIP-Br1 and E2F1 and DP1 expression constructs, we observed a 
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further increase in the E2F1-Luc readout, while PP2A-C and E2F1/DP1 co-
transfection alone did not induce a significant change in E2F1/DP1-driven luciferase 
activity, suggesting that overexpression of the PP2A-C subunit increased TRIP-Br1 
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Figure 3.3.24: Overexpression of the PP2A-C subunit increases the 
level of TRIP-Br1 protein 
 
(A) HK2 cells were transiently transfected with an expression construct encoding the 
PP2A-A, -Bα or -C subunit, or vector only.  Total protein was harvested 48 hours 
post-transfection for immunodetection of PP2A-A, -Bα, -C, TRIP-Br1 and securin. 
(B) The quantitative analysis of the level of various proteins in PP2A-A or PP2A-Bα 
or PP2A-C or vector transfected cells. Antibody signals were quantitatively analyzed 
using Genetools (Syngene, Frederick, MD). The amount of TRIP-Br1, PP2A-A, 
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PP2A-Bα and PP2A-C in PP2A-A or PP2A-Bα or PP2A-C transfected cells relative 
to that of vector transfected cells, which were set to one fold or 100% as indicated, 
were calculated. Average protein levels and error bars representing standard 
deviations were calculated from two separate experiments using Excel. 
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Figure 3.3.25: Overexpression of the PP2A-C subunit does not 
change the level of TRIP-Br1 mRNA.   
 
HK2 cells were transfected with an expression construct encoding the PP2A-C 
subunit.  Total RNA was harvested 36 hours after transfection. (A) The expression 
levels of PP2A-C and TRIP-Br1 mRNA in PP2A-C-transfected cells relative to that of 
vehicle control cells were validated by real-time PCR. GAPDH mRNA was used as a 
loading control. All experiments were performed in duplicate. (B) PCR products were 
analyzed by agarose gel electrophoresis to confirm the presence of the specific 
amplicons. PCR amplification was run for 40 cycles.  
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Figure 3.3.26: Overexpresssion of the PP2A-C subunit decreases the 
level of serine-phosphorylated TRIP-Br1 protein. 
 
(A) HK2 cells were transfected with a plasmid encoding PP2A-C, or with empty 
vector. Endogenous TRIP-Br1 protein was immunoprecipitated 48 hours after 
transfection and probed for phosphoserine with anti-phosphosine antibody (Left 
panel). The blot was stripped and reprobed for TRIP-B1 protein (Right panel).   
(B)The quantitative analysis of the level of ser-phosphorylated TRIP-Br1 protein in 
PP2A-C transfected cells compared to that of vector transfected cells. Antibody 
signals were quantitatively analyzed using Genetools (Syngene, Frederick, MD). 
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Quantitated ser-phosphorylated TRIP-Br1 protein level was normalized to total TRIP-
Br1 protein level loaded first. The amount of ser-phosphorylated TRIP-Br1 protein in 
PP2A-C transfected cells relative to that of vector transfected cells, which were set to 
one fold or 100% as indicated, were then calculated. Average protein levels and error 
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Figure 3.3.27: Overexpression of PP2A-C subunit increases TRIP-
Br1 co-activated E2F1/DP1 transcription. 
 
HK2 cells were transiently transfected with pGL3-TATA6XE2F1 (100 ng) and pRL-
TK (2 ng) luciferase reporter constructs, along with various combinations of pCMV-
E2F1/pCMV-DP1 (100 ng) and pD30-PP2A-HA-C (600 ng) expression constructs as 
indicated. The total amount of transfected plasmids in each treatment was equalized 
using pcDNA empty vector.  Whole cell lysates were harvested and subjected to dual 
luciferase assays. Values represent the average of three independent experiments. 
Fold activation refers to firefly luciferase activity normalized to Renilla luciferase 
activity, and is expressed relative to the normalized activity observed with 
transfection of these dual luciferase reporters alone, which has been arbitrarily set at 
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3.4     Discussion 
Almost a decade has passed since the first member of the TRIP-Br protein family, 
TRIP-Br1, was identified (Sugimoto et al., 1999: Hsu et al., 2001). This was followed 
shortly by the report of the identification of additional TRIP-Br family members with 
accumulating data regarding their cellular distribution, tissue specific expression and 
cellular functions (Cho et al., 2000; Darwish et al., 2007; Nagase et al., 1997; Hayashi 
et al., 2006; Bennetts et al., 2006). Now it is increasingly clear that TRIP-Br proteins 
play an important role in gene transcriptional and cell cycle regulation. 
Overexpression of TRIP-Br1 or TRIP-Br2 or RBT1 in mouse normal fibroblast 
NIH3T3 cells leads to anchorage-independent cell growth and tumor formation in 
nude mice (Darwish et al., 2007; Tang et al., 2005). Knocking down the expression of 
TRIP-Br1 or TRIP-Br2 or RBT1 in human normal fibroblasts and human cancer cell 
lines suppresses S-phase entry and cellular proliferation (Darwish et al., 2007; Tang et 
al., 2005; Sim et al., 2004). This suggests that maintaining normal physiologic 
expression levels of the TRIP-Br proteins is crucial for mammalian cells to ensure cell 
cycle regulation. The potential value of the TRIP-Br proto-oncoproteins as therapeutic 
targets for human cutaneous and intracavitary hyperproliferative lesions further 
highlights the importance of understanding how the TRIP-Br proteins are regulated in 
the mammalian cell.  However, little is known about the functional regulation of the 
TRIP-Br proteins. To address this gap in understanding, we have utilized the approach 
of identifying protein interacting partners to TRIP-Br1 to further decipher the cellular 
regulatory mechanisms of this important protein family. TRIP-Br1 was chosen as a 
representative of this protein family for our studies since it is the most intensively-
studied member and it exhibits many of the known functional characteristics of this 
protein family. 
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Utilizing a GST-mTRIP-Br1 fusion protein, we identified serine/threonine protein 
phosphatase 2A as a cellular interactor of the TRIP-Br1 protein. Kaelin et al used this 
approach (SV40 T antigen/adenovirus E1A-binding domain of pRB fused to GST) to 
successfully identify several pRB interacting proteins (Kaelin et al., 1991). In 
contrast, attempts that employed coimmunoprecipitation (co-IP) pRB from 
metabolically labeled cells lysate failed to demonstrate the existence of a cellular 
pRB-binding protein because of several limitations of this technique in identifying 
protein-protein interactions (Kaelin et al., 1991). First, as in the case of pRB, a large 
portion of the pRB sequence is devoted to T/E1A binding (Hu et al., 1990) such that, 
at least in principle, pRB could become masked by a bound protein. If so, an antibody 
that interacts with this region of the protein surface might preferentially or exclusively 
recognize the unbound form of the protein. This would be especially true if pRB 
ordinarily binds to a large, multimeric complex of proteins that effectively shields key 
epitopes from specific antibody recognition sites. Likewise, for TRIP-Br1 protein, a 
hetertrimeric protein complex like PP2A holoenzyme may effectively shield the 
specific antibody binding site of TRIP-Br1 so that the co-IP using the TRIP-Br1 
antibody may preferentially pull down the unbound from of TRIP-Br1 such that the 
assay may not be sufficiently efficient to pull down a significant amount of interactors 
for visualization and analysis. Second, the amount of interactors pulled down is 
usually proportional to the amount of “bait” or antibody used.  This is usually not a 
limiting factor for the GST-fusion protein affinity purification approach.  For co-IP, 
however, the more antibodies that is used, the wider the resulting immunoglobin band 
will appear by silver staining. This may mask potential interactors in the region of the 
immunoglobin band.  
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As shown in Figure 3.3.2, a panel of four human kidney epithelium-derived cancer 
cell lines including 786-O (human kidney clear cell carcinoma), 769-P (human kidney 
clear cell carcinoma), HEK 293 (human embryonic kidney epithelial immortalized by 
adenovirus type 5 DNA) and HK2 (human adult kidney epithelial immortalized by 
HPV 16 E6/E7 gene) cells were used in this study because they represent a spectrum 
of both low and high endogenous TRIP-Br1 expressing cell lines.  To identify a 
cellular interactor of TRIP-Br1 by screening a mammalian cell extract using GST-
mTRIP-Br as “bait”, a low TRIP-Br1 expression cell line is preferred as it will 
minimize the competition for binding by endogenous proteins. But for the purpose of 
verifying the interaction of candidate interactors with endogenous TRIP-Br1, a high 
TRIP-Br1 expressing cell line is preferred when performing co-IP on endogenous 
TRIP-Br1 protein. Interestingly, 769-P cells have a very low TRIP-Br1 expression 
level and this cancer cell line does not induce tumor formation when injected 
subcutaneously into immune-deficient mice (personal communication, Dr. Lakshman 
Gunaratnam, Brigham and Women's Hospital, Harvard Medical School). 
 
When GST-mTRIP-Br1 fusion protein immobilized on glutathione agarose beads was 
used as “bait” to probe a HEK293 cell lysate, we identified one unique band of 55 kD 
that was not present in GST control binding reactions. The subsequent liquid 
chromatography/mass spectrometric analysis revealed that five proteins were present 
in this band including the Bα and Bδ subunits of PP2A. The specificity of the protein-
protein interaction between PP2A-Bα and TRIP-Br1 was verified in vitro by GST-pull 
down using HEK 293 and 769-P cell lysates and in vivo by co-IP of endogenous 
proteins expressed in 786-O and HK2 cells. Moreover, as PP2A is a heteretrimeric 
complex comprised of a 65 kD scaffolding subunit (A subunit), a 36 kD catalytic 
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subunit (C subunit), and a variable regulatory subunit (B subunit), immunoblots were 
also probed for the A and C subunit with specific antibodies to assess if they were 
also present in the PP2A-Bα-TRIP-Br1 protein complex. Indeed, both the A and C 
subunit were detected in a complex with PP2A-Bα subunit and TRIP-Br1 protein, 
suggesting that the PP2A holoemzyme comprising A/Bα/C subunit associates with 
TRIP-Br1.  
 
More importantly, using a chemically synthesized phosphopeptide “RRApTVA” as 
the substrate, we demonstrated that an OA-sensitive phosphatase is associated with 
GST-mTRIP-Br1 in pull-down experiments performed on whole cell lysates from 
769-P and 293 cells. This phosphopeptide is an excellent substrate for PP2A, although 
it is also with a substrate for PP2B and PP2C (Serine/threonine protein phosphatase 
activity assay kit from Promega) (Donella Deana, A. et al. 1990). PP1 does not 
catalyze the dephosphorylation of this phosphopeptide because of the more stringent 
structural requirements of PP1 (Donella Deana, A. et al. 1990). The fact that PP2A 
exists in complex with TRIP-Br1 both in vitro and in vivo as shown by GST pull-
down and co-IP experiments and direct mass spectroscopic identification strongly 
suggests that the phosphatase activity associated with GST-mTRIP-Br1 pull-down is 
due to PP2A rather than other phosphatases. Moreover, both PP2B and PP2C 
phosphatase activity are not sensitive to the inhibitory effects of OA (Gallego, et al 
2005).  
 
Interestingly, when we compare the amino acid sequence of phosphopeptide 
“RRApTVA”, a known PP2A substrate, with the amino acid sequence of human 
TRIP-Br1, we found a sequence “APSVA” at aa96-aa100 of TRIP-Br1 that resembles 
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“RRApTVA”. The phosphoserine (pS) and phosphothreonine (pT) are interchangeable 
for serine/threonine protein phosphatase 2A (PP2A). PP2A has been shown to be a 
major proline-directed phosphatase although in most cases it deposphorylates serine 
or threonine residues that precede proline (pSer/Thr-Pro motif), such as those present 
in CDC25C and tau (Clarke et al., 1993; Karaiskou et al., 1999; Zhou et al., 2000). 
Moreover, blast search revealed that the serine residue (Ser98) at “APSVA” as well as 
this whole five amino acid sequence is highly conserved among human, monkey, 
chimpanzee, cattle, rat and mouse. Thus, serine 98 (S98) on TRIP-Br1 is suggested to 
be a physiologically phosphorylated site and the sequence “APSVA” may be a 
consensus sequence recognized by PP2A to enable it to dephosphorylate TRIP-Br1 at 
the S98 residue. 
 
After confirming that endogenous TRIP-Br1 and PP2A exist in the same protein 
complex by co-IP studies, we further demonstrated the subcellular co-localization of 
these two proteins to provide support for the plausibility that they are normally 
closely associated with each other. According to the literature, PP2A-Bα is expressed 
in both cytoplasmic and nuclear compartments although the cytoplasm contains more 
Bα while TRIP-Br1 has been reported to primarily localize to the nucleus based on 
immunofluorescence staining of epitope-tagged exogenous TRIP-Br1 protein and the 
pattern of GFP-TRIP-Br1 fusion protein expression (Lai et al., 2007; Sontag, 2001; 
Turowski et al., 1999; Sugimoto et al., 1999). To our surprise, the indirect 
immunofluorescence staining of endogenous TRIP-Br1 protein with our mouse 
monoclonal antibody showed a predominantly cytoplasmic staining pattern, although 
nuclear staining was also present to a lesser degree. This result was confirmed by 
subcellular fractionation performed on both transformed cell lines (HK2 and 786-O 
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cells) as well as untransformed normal diploid fibroblasts (NIH3T3 and WI38 cells). 
In addition, the TRIP-Br1 monoclonal antibody used in our studies was shown to be 
specific by immunodetection of TRIP-Br1 recombination proteins produced by both 
mammalian (Figure 3.3.14) and bacterial cells (Figure 3.3.1, middle panel) as well as 
blocking experiments performed by pre-incubation with an excess of the peptide used 
to generate the original hybridoma (data not shown). Thus, we conclude that 
endogenous TRIP-Br1 is a predominantly cytoplasmic protein in asynchronously 
cycling cells at steady-state, while overexpressed tagged exogenous protein mainly 
localize to the nucleus. This is not surprising because it is well-known that the tagging 
or overexpression of proteins can alter the intracellular localization or the function of 
the target proteins  (Miyashita, 2004). This raises the important and distinct possibility 
that all previous reports of predominant nuclear localization of overexpressed epitope-
tagged exogenous TRIP-Br1 represent an artifact and does not reflect the normal 
physiologic state of intracellular TRIP-Br1 distribution. 
 
TRIP-Br1 is known to interact with the cyclin D-CDK4 complex via binding to 
CDK4 (Sugimoto et al., 1999). It is still currently unclear whether this interaction 
occurs in the nucleus or the cytoplasm. It is noteworthy that D-type cyclins and 
CDK4/6 do not possess obvious nuclear localization sequences (Bockstaele et al., 
2006a). Other CDK4/6 binding proteins including p16INK4α, p15INK4b (Lukas et al., 
1995; Reynisdottir and Massague, 1997) and Cdc37 (Stepanova et al., 1996) are 
predominantly cytoplasmic proteins. In contrast, Cip/Kip proteins contain a well-
characterized bipartite nuclear localization signal (NLS) in their C-terminus. Indeed, 
enforced expression of p21, p27 and p57 has been demonstrated to localize cyclin D-
CDK complexes to the nucleus (Bockstaele et al., 2006b; LaBaer et al., 1997). 
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Deletion of the NLS of p21 and p27 relocalize CDK4 to the cytoplasm (Bockstaele et 
al., 2006b; LaBaer et al., 1997).  TRIP-Br1 has a putative nuclear localization signal 
(NLS) within its N-terminal cyclin A-binding domain (KRKR) (Sugimoto et al., 1999; 
Hsu et al., 2001). We propose that this signal may only be exposed under certain 
conditions such as binding to certain interactors, resulting in translocation of TRIP-
Br1 to the nucleus that may only be transient during critical phases in the cell cycle. 
Tagging TRIP-Br1 with HA, FLAG or GFP may trigger conformational changes that 
expose NLS constitutively, resulting in a non-physiologic state of nuclear distribution 
of exogenous TRIP-Br1 protein. To date, ours is the first report showing that 
endogenous TRIP-Br1 protein is mainly expressed in the cytoplasm. This observation 
together with the co-localization of endogenous TRIP-Br1 and PP2A-Bα in both 
cytoplasm and nucleus in HK2 and 786-O cells further strengthens a model in which 
TRIP-Br1 is involved in a functional association with PP2A in vivo. Our findings may 
also hint at novel functions for this TRIP-Br1 in the cytoplasm or indicate that 
translocation from cytoplasm to nucleus is a regulatory mechanism for controlling 
TRIP-Br1 activity that is important in carrying out its physiologic roles as a 
modulator of gene transcriptional regulation and cell cycle progression. 
 
Reversible protein phosphorylation is a fundamental regulatory cellular mechanism. 
Estimates of phosphorylation in the eukaryotic cell range from 30% of all proteins to 
the “majority of human proteins may be phosphorylated at multiple sites” (Hubbard 
and Cohen, 1993; Zhang et al., 2002). Phosphorylation of substrate sites at serine, 
threonine or tyrosine residues is performed by members of the protein kinase family, 
the second largest family of proteins encoded by the human genome. Protein kinases 
catalyze phosphorylation events that are essential for the regulation of cellular 
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processes such as metabolism, proliferation, differentiation and apoptosis. TRIP-Br1 
has long been proposed to be a phosphorylated protein since this protein bears a 
cyclin A binding motif that is conserved among all TRIP-Br protein family members 
and experimental evidence demonstrates that TRIP-Br1 interacts with cyclin A in 
vitro and in vivo (S.I. Hsu, unpublished data). In addition, serine/threonine protein 
kinase complex cyclin D-CDK4 may also potentially phosphorylate TRIP-Br1 since 
CDK4 was shown to bind to TRIP-Br1 directly (Sugimoto et al., 1999). Identification 
of PP2A holoenzyme as a novel TRIP-Br1-associated protein provides us further 
evidence for the hypothesis that TRIP-Br1 may be a phosphoprotein. Indeed, 
immunoprecipitation of endogenous TRIP-Br1 protein followed by immunodetection 
of phosphorylated serine residues using a specific anti-phosphoserine antibody (Q5) 
showed TRIP-Br1 is a serine-phosphorylated protein. Bioinformatic analysis using 
server Netphos 2.0 also predicts that there are eight potential phosphorylation sites on 
the TRIP-Br1 protein. Seven of these sites are predicted to involve serine residues and 
one site is predicted to involve a tyrosine residue. Notably, one of the predicted 
phosphorylated serine residues (Ser98) is located at putative consensus sequence 
“APSVA” of TRIP-Br1 (aa96-aa100) and may serve as a proline-directed PP2A 
dephosphorylation site. 
 
PP2A is a major family of serine/threonine protein phosphatases that counteracts the 
effects of numerous serine/threonine protein kinases that are present in the cells. It has 
a role in many cellular processes. It is well-documented that PP2A plays a prominent 
role in regulating the protein levels of several oncoproteins including c-Myc, pim-1, 
bcl-2 and securin, either positively or negatively, by acting to dephosphorylate 
specific phosphoserine residues on these proteins (Arnold and Sears, 2006; Gil-
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Bernabe et al., 2006; Lin et al., 2006; Losman et al., 2003; Ma et al., 2007; Ruvolo et 
al., 2002; Yeh et al., 2004).  C-Myc, pim-1, bcl-2 and securin are all potent proto-
oncogenes.  For example, overexpression of c-Myc in cultured cells or transgenic 
animals blocks cell differentiation and induces neoplastic transformation (Coppola 
and Cole, 1986; Evan et al., 1992). Overproduction of securin leads to aneuploidy 
caused by defective sister chromatid separation, resulting in tumor development 
(Jallepalli et al., 2001; Lengauer et al., 1998). In addition, upregulation of these 
proteins is also found in a wide variety of human tumors.  On the other hand, the 
regulated expression of these genes is essential for the maintenance of normal cellular 
function. For example, cells lacking the c-Myc gene cease to proliferate and exit the 
cell cycle (de Alboran et al., 2001; Trumpp et al., 2001). The securin proteins of 
fission yeast (Cut2) and Drosophila (PIM) are required for sister chromatid separation 
(de Alboran et al., 2001; Funabiki et al., 1996; Stratmann and Lehner, 1996). Thus the 
ability to maintain the physiologic expression of these genes is crucial in order for 
cells to undergo normal growth. In the case of c-Myc, its protein level is controlled by 
the balance between the Raf–MEK–ERK pathway which stabilizes c-Myc by 
enhancing Ser62 phosphorylation and the AB'αC PP2A holoenzyme which 
dephosphorylates Ser62 and negatively regulates c-Myc accumulation (Yeh et al., 
2004).  Securin levels are kept in balance between phosphorylation by the mitotic 
kinase Cdc2 (Ramos-Morales et al., 2000) or DNA-protein kinase (Romero et al., 
2001) and dephosphylation by the ABδC PP2A holoenzyme (Gil-Bernabe et al., 
2006). Overexpression of PP2A leads to accumulated securin protein and the 
inhibition of PP2A activity by okadaic acid decreases the steady state level of securin 
(Gil-Bernabe et al., 2006). 
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TRIP-Br1, a well-documented proto-oncoprotein, is very similar to the c-Myc, pim-1, 
bcl-2 and securin in that increased or decreased TRIP-Br1 protein levels appear to 
alter normal cell growth (Sim et al., 2006; Sugimoto et al., 1999; Tang et al., 2005). 
The fact that TRIP-Br1 is a serine-phosphorylated protein and that it associates with 
PP2A encouraged us to test the possibility that manipulation of PP2A activity may 
have effect on the serine phosphorylated form of TRIP-Br1 as well as the steady-state 
level of the TRIP-Br1 protein. We demonstrated that inhibition of PP2A activity by 
okadaic acid (OA) resulted in a decrease in total TRIP-Br1 protein and an increase in 
serine-phosphorylated TRIP-Br1 levels. OA has been shown to preferentially inhibit 
PP2A at the low concentration used in these experiments. However, we could not rule 
out the possibility that OA may inhibit other phosphatases to some degree. 
Nevertheless, two observations strongly implicate PP2A in the regulation of TRIP-
Br1 protein level. First, decreasing cellular PP2A activity achieved by using RNA 
interference directed against the catalytic subunit of PP2A, led to a reduction in 
cellular TRIP-Br1 protein expression. Second, increasing the cellular levels of the 
PP2A catalytic subunit of PP2A promoted the accumulation of cellular TRIP-Br1 
protein levels. The serine-phosphorylated form of TRIP-Br1 accumulated upon OA 
treatment while the total TRIP-Br1 protein level decreased, suggesting that inhibition 
of PP2A-mediated dephosphorylation of TRIP-Br1 may promote the degradation of 
TRIP-Br1 protein and that PP2A may positively regulate the protein level of TRIP-
Br1. Consistent with this hypothesis, overexpression of PP2A catalytic subunit 
decreased the level of the serine-phosphorylated form of TRIP-Br1 and increased the 
steady-state level of TRIP-Br1. Overexpression of the Bα subunit was expected to 
have an effect on accumulation of endogenous TRIP-Br1 protein. However, we did 
not observe such an effect probably due to the insufficient expression level of Bα 
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transgene achieved (about 20-30% increase relatively to the endogenous Bα level). 
Overexpression of PP2A-A had little effect on the TRIP-Br1 protein level, suggesting 
that the PP2A scaffolding subunit may not be a limiting factor for the PP2A-mediated 
regulation of TRIP-Br1. Interestingly, an aberrant effect on c-Myc was observed from 
overexpressing PP2A-A (Arnold and Sears, 2006). Although the c-Myc protein level 
decreased upon PP2A-C and -B subunit overexpression, overexpressing the PP2A-A 
subunit led to an increase in c-Myc protein levels for reasons that are still currently 
unclear (Arnold and Sears, 2006). In addition, we also demonstrated that alterations of 
endogenous TRIP-Br1 protein level by transcriptional silencing or overexpression of 
PP2A-C are due to the post-translational modification of TRIP-Br1 protein by PP2A, 
rather than the direct effect of decreased or increased TRIP-Br1 transcript, as real-
time PCR revealed that the mRNA of TRIP-Br1 remains constant when the protein 
level is altered.  
 
All of the four classic mammalian TRIP-Br protein family members (TRIP-Br1, 
TRIP-B2, RBT1 and CDCA4) are reported to possess potent intrinsic transcriptional 
activity (Cho et al., 2000; Hsu et al., 2001). In particular, TRIP-Br1, TRIP-B2, and 
RBT1 are demonstrated to co-activate the transcriptional activity of the E2F1/DP1 
complex, presumably via physical interaction with DP1 (Darwish et al., 2007, Hsu et 
al., 2001).  In this study, we showed that co-transfection of PP2A-C and TRIP-Br1 
expression constructs further increased TRIP-Br1 co-activation of E2F1/DP1 
mediated-transcription.  This suggests that increased TRIP-Br1 protein levels 
resulting from overexpression of PP2A-C may be functionally significant. Notably, it 
has been observed that inhibition of PP2A activity results in mammalian cell cycle 
arrest in the G1 phase of the cell cycle, which correlates with a decrease in the cyclin 
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E protein level and attenuated CDK4 protein kinase activity (Schonthal and 
Feramisco, 1993; Yan and Mumby, 1999). As TRIP-Br1 is a transcriptional regulator 
that is essential for the induction of cyclin E expression, S-phase entry and cell cycle 
progression (Sim et al, 2006), it is possible that decreased TRIP-Br1 protein levels 
may contribute to the G1 arrest of mammalian cells upon inhibition of PP2A activity 
through an effect on TRIP-Br1-mediated E2F1/DP1 transcriptional activation (Hsu et 
al., 2001). 
 
Taken together, we propose that the ABαC PP2A holoenzyme associates with and 
positively regulates the protein level of the proto-oncogene TRIP-Br1. Our results 
suggest that PP2A, which has been traditionally considered to be a tumor-suppressor, 
is able to exert positive effects in cell growth and proliferation as well. Indeed, PP2A 
positively regulates the protein level of proto-oncogene Bcl2 and securin.  As 
overexpression of PP2A has been found in transformed cell lines as well as 
chemically-induced rat liver tumors (Kitagawa et al., 1988a; Kitagawa et al., 1988b), 
deregulation of this PP2A-mediated process may contribute to tumor formation, a 
process in which the overexpression of TRIP-Br1 has been implicated (Li et al., 2005; 
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                            CHAPTER FIVE 




In conclusion, in an effort to determine the potential chemotherapeutic effect of 
antagonizing the TRIP-Br1 and TRIP-Br2 integrator function for the treatment of 
cutaneous and intracavitary hyperproliferative lesions, we utilized Penetratin-tagged 
synthetic decoy peptides that compete with TRIP‑Br for binding to PHD zinc finger- 
and/or bromodomain-containing proteins and demonstrated that: 
 
1. Antagonism of the integrator function of TRIP-Br1 or TRIP-Br2 triggers dramatic 
anti‑proliferative effects and induces nuclear sub‑diploidization in representative 
human nasopharyngeal cancer (CNE2), cervical cancer (Ca Ski) and melanoma 
(MeWo) cancer cell lines in vitro.  
 
 2. TRIP-Br decoy peptides are effective at inhibiting the growth of NPC2-, Ca Ski- 
and MeWo‑derived tumors in the chick embryo chorioallantoic membrane xenograft 
model.  
 
3. The integrator function of TRIP‑Br may represent a novel chemotherapeutic target 
for the treatment of human cutaneous and intracavitary hyperproliferative lesions. 
 
To further understand the functional regulation of the TRIP-Br1 proto-oncoprotein, a 
potential therapeutic target for human cutaneous and intracavitary proliferative lesions, 
we utilized a GST-mTRIP-Br1 fusion protein as “bait” to identify cellular interactors 
in mammalian cell extracts and demonstrated that: 
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1. Serine/threonine protein phosphatase 2A (PP2A) holoenzyme ABαC associates 
with TRIP-Br1 in vitro and in vivo in mammalian cells.  
 
2. In contrast to exogenous overexpressed tagged-TRIP-Br1 protein, endogenous 
TRIP-Br1 protein is predominately expressed in the cytoplasm of the cell, although 
staining is also found in the nucleus to a lesser extent. Endogenous PP2A-Bα protein 
co-localizes with TRIP-Br1 in the cytoplasm as well as the nucleus. 
 
3. TRIP-Br1 protein is phosphorylated on serine residues, presumably by cyclin A-
CDK2/cdc2 or cyclin D-CDK4 through physical interaction of TRIP-Br1 with these 
serine/threonine protein kinase complexes. 
 
4. PP2A positively regulates the protein level of TRIP-Br1. Deregulation of this 
PP2A-mediated process may contribute to cellular transformation and tumor 
formation, 
 
In the next phase of study, we propose to extend the evaluation of peptide inhibitors 
of TRIP-Br integrator function from chick “CAM” tumor model to a mouse model of 
cutaneous and mucosal hyperproliferative lesions. A transgenic mouse model 
overexpressing the E6 and E7 oncoproteins of human papillomavirus (HPV), the virus 
that causes cervical cancer in humans, have been recently shown to develop 
hyperproliferative lesions at cervical mucosal epithelia upon exposure to estrogen 
(Shai et al, 2007). This mouse model is ideal for our next phase of “proof-of-principle 
study” of therapeutic potential of TRIP-Br1 decoy peptide since it is the only animal 
model in which cervical cancer occurs at the cervical os (opening to the cervix) upon 
estrogen induction—the location and conditions that perfectly mimic the human 
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setting in which cervical cancer develops. A decoy peptide-impregnated vaginal 
suppository (a semi-rigid “tampon-like” drug delivery system) that is capable of 
releasing the peptide slowly will be designed in collaboration with the pharmacist in 
the University of Florida. Drug delivery efficiency will be determined. The mice 
bearing superficial cervical neoplasia will be divided into five groups and treated with 
peptide-impregnated vaginal suppository that contains 100-1000 µg of “TRIP-Br1”, 
“TRIP-Br2”, “scrambled” peptide or “vehicle” respectively, starting from 3 month 
after of 17-estradiol exposure. The in vivo data from this mouse cervical cancer model 
will provide further evidence on the efficacy and feasibility of the TRIP-Br decoy 
peptide based therapy in human cutaneous and intracavitary hyperproliferative 
lesions. 
 
With regard to the PP2A-mediated TRIP-Br1 regulation, we propose to further 
identify the phosphorylated serine residue on TRIP-Br1 that is the target of PP2A as 
wells to identify the kinase that is responsible for phosphorylation of this residue. 
Site-directed mutagenesis will be applied to the speculated Ser98 residue on TRIP-
Br1 to test if this is the critical site for TRIP-Br1 regulation by PP2A. If this proves to 
be the case, a specific antibody for phosphoserine at position S98 of TRIP-Br1 can be 
generated. Such an antibody will be a useful tool to further understand the regulation 
and functions of the TRIP-Br1 protein and to allow for high throughput screening of 
human tumor tissue microarrays for alterations of the phosphorylation state at this 
site. Mapping the interaction region of TRIP-Br1 with PP2A will also be important, as 
this will allow us to investigate the mutant form of TRIP-Br1 protein. 
In summary, although our studies of the regulation of the TRIP-Br1 proto-oncoprotein 
and the evaluation of the feasibility of antagonizing the TRIP-Br integrator function 
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as a potential transcription-based chemotherapeutic target for hyperproliferative 
lesions have generated data that advance current understanding of this fascinating 
oncogene family, much work remains to be done to uncover the precise mechanisms 
by which TRIP-Br proteins are regulated in cells as well as the their therapeutic 
significance in human diseases. Uncovering the mechanism of TRIP-Br protein 
regulation will facilitate the application of therapeutic strategies targeting TRIP-Br 
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